weiver ni raey roche faced weathered many challenges nearly years solidarity community experience fight covid significantly increase collaboration doubt come even stronger severin schwan ceo roche group see video roche strongercontents reliable partner management perspectives reporting strategy supporting patients business review corporate governance remuneration report strdoing patients need next strongertogetherwe believe urgent deliver medical solutions right even develop innovations future passionate transforming patients lives courageous decision action believe good business means better world come work day commit scientific rigour unassailable ethics access medical innovations today build better tomorrow proud many working one across functions across companies across world rocherentrap elbailer anoroc eht gnirud cimednapa reliable partner roche reports began appear somewhat quietly early soon alarm began ring loudly virus called sarscov suddenly dominating headlines threatening lives around world roche quickly realised company new mission substantial list vital undertakings list included developing new diagnostic tools determining existing medicines could combat infection ease symptoms developing entirely new medicines treat virus joining forces governments business partners organisations accelerate progress securing employee safety maintaining business continuity ensure supplies tests medicines reached patients need nikki student university california berkeley recovering covid enjoying life spending time favourite outdoor activities see nikkis storya reliable partner roche doesnt get closer home nearly three years ago roche employee michaela received positive result nikki consulted harts daughter nikki diagnosed doctors using telemedicine travelling healthcare significant illness march nikkis workers came check vitals administer latest hospital visit treatment something seemed treatments including intravenous fluids new different way partially opened apartment door nikkis main concern michaela says infect others friday th explains michaela vice president quality systems compliance taking charge healthcare gave roche diagnostics pleasanton california nikki sense control michaela says involved started feeling sick discharged medical sleuth gave way hospital yet could owning diagnosis really important result ongoing treatments point patients underlying illness repeated face new possibility could covid episodes severe dehydration nikkis recovery long journey handling well nikki became sick continue really struck michaela daughters strength education university california berkeley trust part roche familyboth family moved home hopes patient daughter employee nikki would soon return school kept nikkis mindset positive strong offcampus apartment goal keep michaela says everything normal possible hope best throughout career michaela remained focused champion quality started feeling really sick considering voice perspective usual ways michaela explains hard customer patients daily workplace said could covid decisions moment michaela said youd better selfisolate apartment get realised time customer sick cant take care daughter get closer home nikki returned apartment soon became even sicker high fever doctor recommended tested covid involved test came back negative nikki unconvinced said mother know covid medical sleuth gave way flu feel different different virus owning diagnosis really nikki insisted another covid test important patients weeks waiting several phone calls future hinges partnerships looking back experience covid development goals experience painful alain bindels head innovation realised importance solidarity facilitation digitalisation roche explains sustainability building ecosystems make tough moment life really felt change happen helpless realised fragile life really two weeks knowing outcome opportunity harness solidarity around would get better able see globe family disease transformed alain well annual innovation summit organises recover alain says observed creativity agility spurred man virus days pandemic recognised opportunity harness back fever high degrees celsius solidarity around globe alain saw power loss oxygen blood stumbled uniting innovators across pharma government bed one word everpresent mind academia startups nonprofits individuals solidarity work together deliver solutions matter patients registrations missed connections became clear external companies joining including companies covid alain began see connections euvsvirus hackathon roche world missed sponsor partner find solutions covid realised importance sustainability society community individual alain wish future built firmly believes futurepersonally ecosystem partnerships startups universities professionallyhinges partnerships experts private companies even ngos put patient centre alain think way go forward covid says focus determining collaboration helping bring worlds together functioning alain says honest became sick ecosystem thats centred around patient needs focused sustainability sustainable life fragile asked surprised experience covid patient alain says fragility life connections pandemic demonstrates vulnerability allowed see part big community big world take benefit uniting innovators across care says think life fragile societies fragile really want create pharma government academia positive future sustainable future everybody need rethink working society startups nonprofits individuals community also personal levela reliable partner roche alain head innovation facilitation digitalisation roche states person contracting sarscov infection one word everpresent mind solidarity see alains story support high demand sarscov testing increased production capacity unparalleled levels allocation strategy ensures tests consumables systems made available needed effective thomas schinecker ceo roche diagnosticsa reliable partner roche researching novel coronavirus urgent search solutions throughout human history pandemics end first quarter first roche afflicted world fact inevitable pcr diagnostic test identify active infection part life earth global challenge approved launched record time covid one worst modern history global scale combating virus demands modern approach joining forces unprecedented show solidarity urgency quick start april multinational group consisting complete genome sequence sarscov global health regulatory agencies determined made public january dozen leading biotech companies many almost immediately initial outbreak renowned academic researchers banded together virus genome sequences followed quickly battle disease knows borders world collaboration called accelerating covid therapeutic interventions vaccines activ sequence availability provides vital blueprint develop new tests diagnose virus drugs effort led national institutes health fight nih foundation nih public private partnership truly pandemic proportions summoning resources brings together wide range experts including early pandemic roche initiated internal industry rd leaders director nih research programmes develop sarscov director national institute allergy tests discover potential drugs combat infectious diseases health human services virus roche also established internal office assistant secretary preparedness review team rapidly evaluate large number response centers disease control potential partnering opportunities determine prevention us food drug administration complemented expertise held fda european medicines agency ema promise roche also provided support external collaborators including krogan lab global challenge covid university california san francisco identify possible new therapeutic approaches existing one worst modern history fdaapproved medicines another collaboration calibr scripps research involved roche combating virus demands providing several discovery stage compounds screening potential antiviral activity modern approach sarscov since april entire activ group gathered addition roche entered private weekly basis one virtual room share public partnership barda advance align develop coordinated global response development medicines infectious diseases goals activ straightforward prioritise significant unmet need best vaccine drug candidates streamline part agreement barda provide funding clinical trials regulatory processes share support development baloxavir knowledge tools amongst partners order marboxil severely ill hospitalised influenza respond covidand future pandemics patients potential funding quickly possible studies key aspect approach willingness safeguarding ongoing clinical studiesand people industry academia government participants even private foundations work together make march steep rise sarscov infections difference effort strives break began capture great deal attention traditional boundaries silos normally slow resources roche time company progress openness transparency collaboration took significant measures ensure ongoing shared goal addressing global health clinical studies conditions continued crisis important attributes uninterrupted study participants unprecedented collaboration especially cancer trials often advanced stages disease roche went roche evaluating safety efficacy great lengths ensure protected actemraroactemra hospitalised adult patients possible severe covid pneumonia part effort collaboration biomedical advanced study teams asked flexible research development authority barda empowered take whatever steps necessary part us department health human protect patients approach unusual services collaboration first time also effective across functions teams roche combined forces barda back developed multiple ways protect patients roche entered multiyear publicprivate without disrupting studies methods partnership federal authority effort adjusted meet specific needs jointly combat rise antibiotic resistance level individual patient requirements development new antibacterial drugs result planned pivotal trial starts filings pointofcare diagnostics drug launches remain largely tracka reliable partner roche covid changed way many things lots positive ways really given huge sense purpose mission actually science william pao head roche pharma research early development predthe ongoing complexities covid require multiple lines defence joining forces companies hope offer additional treatment options hospitalised nonhospitalised covid patients ease burden hospitals global pandemic bill anderson ceo roche pharmaceuticalsa reliable partner roche partnershipsbuilt combining strengths developing anticovid medicines partnership agreements clear examples people around globe continue struggle amazing things accomplish covid pandemic become efforts aligned common vision clear solutions needed quickly since keep patient centre everything early roche focused relentlessly everything possible help people communities impacted covid one efforts global partnering innovative drug discovery partnership regeneron collaborate platform technologies development manufacturing distribution working together stakeholders investigational covid antibody combination crucial combating covid pandemic casirivimab imdevimab vital fighting noncovidrelated diseases spite pandemic succeeded antibody combination currently adaptive establishing new partnerships focused studies targets specifically sarscov developing latest scientific innovations consists two noncompeting virusneutralising bringing patients multiple collaboration antibodies casirivimab imdevimab agreements also support efforts increasing administered together bind critical efficiency drug discovery across different receptorbinding domain viruss spike protein therapeutic areas may diminish risk viral escape key partnership examples include initial data ongoing study showed reduction viral load decrease medically attended blueprint medicinesroche visits non hospitalised patients covid licence collaboration agreement new november fda granted emergency personalised treatment gavreto pralsetinib use authorization eua casirivimab patients retaltered nonsmall cell lung imdevimab cancer nsclc medullary thyroid carcinoma types thyroid cancers solid tumours leading biotech manufacturer roche well placed help bring new therapy patients part global regeneron partnership committing significant amount manufacturing capacity working expand supply partnership agreements antibody combination beyond us many people possible clear examples amazing things october partnership atea pharmaceuticals accomplish efforts inc announced develop manufacture distribute ateas investigational oral direct aligned common mission acting antiviral people around globe reverie labsrochegenentech vividionroche multitarget collaboration agreement utilise collaboration licence agreement develop artificial intelligence ai drug discovery smallmolecule medicines difficulttodrug reveries machine learning platform promises intracellular targets vividions proprietary drug augment accelerate drug discovery discovery platform help address range increasing power predictive algorithms targets interest pred across oncology relevant smallmolecule properties pred immunology roche provide binding gred leverage platform several ligands defined targets nominated smallmolecule kinase programs supporting collaboration roches aim delivering twice many medical advances society half cost addition new drug discovery technologies roche entered multiple new partnerships arrakisroche ranging across different therapeutic areas collaboration licence agreement develop modalities include rnatargeted small molecules across several disease areas arrakis developed pioneering bicycle therapeuticsgenentech drug discovery platform integrates rna collaboration agreement discover develop bioinformatics structural tools commercialise novel bicycle therapeutics based comprehensive proprietary screening process immunooncology therapies platform identify small molecules impact broad set targets across pred forgeroche disease areas arrakis lead initial research collaboration identify develop novel activities roche conduct rd antibiotic treating serious lung infections commercialisation attributed antibioticresistant gramnegative bacteria samsung harman internationalroche collaboration research agreement develop digital therapeutics platform autism digital health products ucbgenentech development commercialisation agreement develop manufacture commercialise ucb middomain antitau antibody treatment alzheimers disease collaboration agreements also inflazomeroche support efforts increase acquisition oral smallmolecule inhibitors nlrp complement roches existing efficiency drug discovery across immunology neuroscience portfolios provide potential addon combination multiple therapeutic areas products developmenta reliable partner roche became obvious ever working together stakeholders crucial combating covid pandemic ensuring slowing innovation across disease areas james sabry global head pharma partnering thanks hard work dedicated staff roche deliver high doubledigit millions tests per month see sarscov diagnosisa reliable partner roche safeguarding operations scientists roche continued work reagents consumables sarscov testing tirelessly throughout year develop laboratories use magna pure entire portfolio tests solutions help lightcycler systems course year fight pandemic production output pcr tests increased fourfold stepping patients swift development sarscov diagnostic solutions pcr test soon followed launch across roche diagnostics manufacturing elecsys antisarscov antibody test distribution sites rapid response teams received fda eua may serology worked around clock produce deliver test designed help accurately assess prior commercial tests detect novel coronavirus infection sarscov determine patient developed antibodies march pcrbased cobas sarscov virus information essential epidemiologic test received fda eua first would studies ongoing surveillance vaccine studies become comprehensive portfolio solutions quickly began shipping new antibody test help combat pandemic within hours leading laboratories globally ramped receiving authorisation fda production capacity high doubledigit millions manufacturing team branchburg new jersey per month serve healthcare systems us sent test kits door colleagues countries accepting ce mark hospitals indianapolis distribution centre began shipments reference laboratories run test within us two days later roches cobas e analysers widely available around world zero million record time tremendous personal commitment effort crossfunctional collaboration made possible develop produce distribute first test within weeks since approval millions tests delivered globally accordance allocation strategy providing tests needed across roche diagnostics sites effective emergency response teams worked provide millions tests per month highthroughput cobas systems around clock develop produce roche molecular systems teams branchburg worked around clock multiple task forces deliver diagnostic tests used created maximise production capacity maintaining health safety manufacturing combat pandemic personnel addition continued supply scaling production medicines meet asked conduct intercompany demand technology transferthe precise process producing biologics complicated time transferring skill knowledge technologies consuming best circumstances methods producing specific products process persuading live cells produce processes one roche manufacturing site biological medicine exacting highly technical another transfer takes incredible amount biologics based large complex planning attention detail close coordination proteins produced cells cells ensure production transferred living one needs careful tending one site another alignment rigorous sterile environment constant monitoring parameters controls quality systems strict documentation government regulatory approval move vital regulatory rules making sure enough medicines would available patients march many countries moving lockdown response everwidening pandemic technology transfer normally takes time roche expert teams around world months hillsboro team completed ramping goal supplying needed process four weeks without compromising medicines rely making quality safety secret quick much medicine possible might nimble giving teams clear focus defined need later goals power make decisions early march request came team product plane day genentech fill finish facility hillsboro manufactured precise transportation oregon liquid biologic medicines scheduling crucial early transfer transferred large batches smaller vials process team quickly discovered labelled packed prepared shipping flights available get medicines across globe destinations within us around world roche supply chain experts helped team track target flights needed meet demand tight schedule undertaking like typically takes days production planning releasing shipping hillsboro team completed team completed complex task job days four weeks instead months despite lockdown social distancing uncertainty home schooling challenges without compromising quality team worked nonstop shifts seven days week midmarch july finally july safety holiday took short break see technology transfera reliable partner roche rewarding six months career proud achievements made impact make patients society hillsboro employee working nonstop shifts seven days week midmarch july throughout course pandemic roche production logistics teams repeatedly proven expertise excellence deep commitment serving patients worldwidea reliable partner roche tirelessly tenaciously keeping system running many worked home curb spread manufacturing logistics teams coronavirus roche sites around world continued operate uninterrupted around across roche organisation clock working tirelessly tenaciously manufacturing logistics teams across continued produce ship organisation continued produce ship urgently needed medicines tests medicines tests people everyday heroes roche always understood importance work knew needed urgently even important pandemic fully realised gravity mission patients cancer autoimmune diseases heart disease rare conditions depended treatments agility crucial examples include threeyear pandemic present supply old child haemophilia risk logistics challenges thanks resilience running vital hemlibra supplies due global network disruptions lockdown medicine could delivered minimal roche continued deliver crucial regular coldchain logistics companies tests lifesaving medicines patients around local roche team took action reviewing range world roche working urgently accelerate possible solutions finding way ensure manufacturing capacity order maximise family received medicine time production critical tests medicines treatment continued uninterrupted goal increasing available supply globally another illustrative example comes roche committed delivering many combined efforts highly motivated teams coronavirus tests possible areas roche pharma basel roche hub singapore needed tests shipped roche diabetes care thanks work roches production sites locations units medication medical appropriate infrastructure place testing products loaded onto joint oneroche begin without delay charter flight delivered myanmar lockdown accessible commercial roche works ensure coordinated global flights road special solution helped overview additional supply requests provision save lives providing medication patients needed medicines managed country level including tecentriq kadcyla herceptin accordance local rules regulations accuchek roche diabetes care close collaboration local authorities pandemic spread across globe research operational level finance performed roche finance organisation kept watch tasks successfully without trial runs entire enterprise providing expertise needed success due technology automation navigate uncertainty keep company importantly expertise experience course unprecedented collaboration teamwork among affiliates headquarters service teams time heightened need finance team provided insights transparency record procurement teams partnered closely speed supporting unfolding strategic dialogue suppliers work wonders accelerated decisionmaking across organisation contracting help set covidrelated strategic guidance kept funding flowing helping actemraroactemra trials twelve days protect business continuity ensure minimal opposed six months sourced materials impact rd pipeline still able ensure business continuity procured time invest confidence longterm critical blood samples essential scientists develop covid antibody assay five million personal protective equipment items including surgical face masks sourced delivered organisations including agile flexible ways working suppliers companies need spirit procurement provided supplier demonstrated throughout covid financing making established newly developed financial solutions available partner pandemic procurements companies within days agile flexible ways working demonstrated throughout covid new normal pandemic procurements new normala reliable partner roche like many healthcare workers others responded covid ive struggled balance work needs needs family im exhausted proud say able release test thats going used many countries throughout world test millions people pleasanton employee roche molecular systems california countries recognise together lot effort regulatory front improve access covidrelated products domestic consumption also exports support economies harjit gilla reliable partner roche technology critical factor containing outbreak world fights pandemic harjit gill ceo scrambling manage outbreak asia pacific medical technology association medical technology industry doubled apacmed shares lessons learned far efforts ramp production explains role regulators preparing region challenges future harjit gill describes steps governments asiapacific taken streamline regulatory social distancing selfisolation flattening processes ensure availability important curve slowly found way everyday resources fight growing pandemic conversations yet nothing could prepared include accelerating approvals medical world pandemic facing products personal protective equipment put strain collective resources way diagnostic test kits enabling euas life explains harjit gill diagnostics unapproved products approved alternatives core sustainable healthcare role available ever critical containing outbreak helping identify infected patients early testing taking advantage digital technologies prevent communitywide transmission healthcare ensure access timely treatment race weve seen public private sectors ramping bring muchneeded equipment testing technologies adoption digital technologies treatments countries health authorities telehealth case tracking contact tracing working around clock ensure regulations aiassisted diagnosis software remote trainings meet needs constantly changing could push wider deeper utilisation environment digital technologies entire ecosystem would much better prepared next crisis sudden emergence rapid transmission states harjit gill covid devolved global health crisis current healthcare systems faced highly infectious nature novel coronavirus led countries taking drastic actions prevent widespread transmission emergence severe diagnostics core acute respiratory syndrome sars middle east respiratory syndrome mers recently sustainable healthcare role ebola highlighted gaps plaguing healthcare systems every outbreak reached pandemic ever critical containing level twothirds worlds healthcare systems illprepared pandemics according outbreak global health security index report hospitals httpswwwghsindexorgwpcontentuploadsglobalhealthsecurityindexpdf utilising telemedicine safely help patients technology medicine pharmaceuticals safety adding artificial intelligence algorithms never powerful important whole slide image analysis offers potential examples demonstrate roche utilising bring important new information pathologists new technologies help patients safely profoundly impact patients tools replace pathologiststhey enable digital pathology serves patient efficient confident diagnoses clinician spread covid added new challenges precise diagnostics lead effective well element actual physical danger treatment practice pathology physicians many new tissue tests cancer require high staffs higher risk exposure virus level quantitation determine specific site hospital laboratory digital subtype cancer whether patient pathology enables remote diagnoses qualifies targeted therapy assays emerged vital technology depend tumour immunecell counts along precise estimates tumour area roche offers comprehensive solution cases combinations biomarkers supports pathologists transition slideor multiplex assaysgive pathologist digital era technology enables ability pinpoint molecular drivers pathologists collaborate anywhere cancer raise confidence selecting world primed make important contribution best treatment plan patient complex telehealth future assays difficult interpret manually benefit greatly image analysis algorithms ability diagnose patients location support evaluation pathologist particularly crucial global pandemic digitising glass slide powerful whole lung cancer provides helpful example slide scanner integrating result past treatment options workflow tool like upath enterprise software patients disease today collaboration significantly boost efficiency therapies treat disease important ever patients get precise diagnosis new tools technologiesincluding ceivd upath pdl sp image analysis algorithm nsclcaid medical teams determining effective treatment patient based standardised precise consistent ability diagnose patients methods endtoend solution slide scanning full digital workflow automated location particularly critical image analysis roche digital pathology provides complete solution healthcare providers benefit global pandemic transitioning digital eraa reliable partner roche people underlying diseases face higher risk severe illness course covid reduce risk social distancing telemedicine important factors avoid infection maintaining access medical counselling care bringing true relief integrated personalised diabetes management enabled open ecosystem assess needs structured therapyadapted data monitoring assess effectiveness structured documentation personalise treatment collaborative reviewa reliable partner roche diabetes care change significantly covid pandemic boost adoption digital technologies vital seamlessly connecting people diabetes healthcare professionals people diabetes similar risk contracting covid general population become infected face higher risk people diabetes outside conventional severe illness maintaining blood glucose levels health checkups therapeutic target rangeboth short longtermis crucial reducing likelihood effort expand selfsupport capabilities serious covid disease background people diabetes worldwide roche decided social distancing limited access healthcare early covid pandemic provide free posed additional challenges nearly half access pro version patientfacing mysugr billion people living diabetes worldwide app app enables patients share data healthcare professionalswhich even diabetes demands constant monitoring important time patients spending patients make numerous treatment decisions significantly less time physicians throughout day regarding diet exercise medication many decisions made app integral part open ecosystem patients ideally close coordination offers features like structured logging physician covid pandemic documentation therapyrelevant data accurate diabetes care change significantly insulin dose calculations reminders engaging boost adoption digital technologies challenges coaching help people better essential roche able facilitate shift manage daily diabetes routine strategy integrated personalised diabetes management ipdm recent years roche december roche announced partnership developed open ecosystem diabetes care diabeloop french medtech company enables meaningful interaction partnership roche entered people diabetes physicians field automated insulin delivery help advance management insulin pump therapy january roche launched accuchek insight insulin pump roches rochediabetes care platform key component first pump automatically doses insulin based open ecosystem utilised healthcare readings continuous glucose monitor professionals integrates data thus lowering burden people diabetes devices solutions roche partners daily therapy management sharing diabetes competitors platform designed relevant data integrated solutions contextualise data points smart algorithms proven especially beneficial time face provide actionable insights toface visits limited remote consultations personalised approach diabetes care several become preferred method ensuring additional solutions platform introduced uninterrupted support systematic throughout included rochediabetes approach ipdm centred physicianpatient insulinstart service enables easy transition interaction roche strengthened connection insulin therapy people type diabetes patients care teams helping well rochediabetes remotecare solution people diabetes confidentially manage allows healthcare professionals monitor condition covid pandemic new options patients diseases covid dominates public discussion estimates women globally die year many people combating serious diseases disease nearly preventable roche continues research development proper screening vaccination treatment activities multiple disease areas including roche focuses science behind hpv known oncology immunology infectious diseases cause almost cases cervical cancer help ophthalmology neuroscience provide answers aid clinical decisionmaking around patient care new therapy spinal muscular atrophy allie yearold lives spinal muscular advanced objective pki biomarker technology atrophy sma type never treatment nextgeneration triage solution women youtube channel chronicled test positive highrisk hpv technology journey leading receiving evrysdi story offers significant improvement risk stratification includes fda approval evrysdi learning compared traditional pap cytology impact doctor approved receive improving primary screening colposcopy triage treatment culminates heartwarming video trial nearly women landmark cervical taking first dose experience going cancer screening study supported multiple fda forward video shows caregiver assisting approvals received include cintec administering evrysdi allie noting plus cytology cobas hpv use cobas treatment big deal hopeful systems cobas hpv test identifies thankful scientific advancements women risk cervical cancer detecting allow stay alive longer live presence highrisk hpv dna cervical samples additionally cintec plus cytology first hpv testing prevent cervical cancer triage test based dualstain technology using roche made significant strides womens biomarkers p ki identify women health improvements cervical cancer risk may benefit immediate screening triage diagnostic testing followup together cintec histology p biomarker test used cervical biopsies provide clear diagnostic confirmation cervical lesions due hpv innovations advance goal eliminating cervical cancer estimates patient perspective also comes within women globally die year many roche employees also patients caregivers personal lives deal cervical cancer nearly illnesses types covid breast cancer diabetes diseases central nervous preventable proper screening system many experiences gained expertise areas beyond vaccination treatment regular work responsibilitiesa reliable partner roche approvals medicines rare diseases make meaningful difference people living conditions support physicians treat also exemplify patients industry academia authorities find solutions together eva joseph looks microscope cancer tissue sections glass slides slides explained eric walk chief medical officer roche tissue diagnostics tucson arizona site visit november see triple negative breast cancera reliable partner roche covid dominates public discussion many people combating serious diseases enable many people possible benefit substantial experience expertise carering established internal community herneuare expressed tumour making provides framework roche employees share difficult treat experiences support reassure colleagues fighting disease alone fortunately evas oncologist told new carering also effective way support clinical study chance survival quickly commitment putting patient centre formidable team side roche cancer every effort programme employees immunotherapy medicine roche diagnostic share insights experiences roche test along powerful collaboration business teams early product development diagnostics pharmaceuticals teams process carering members also help inform delivered market brought new hope strategy discussions communication efforts eva patients diagnosis including covid pandemic amazing said eva whose tumours nearly vanished feel blessing able first year employees around receive treatment wasnt many world joined carering members active others groups dedicated expansive range health issues carering results quick promising eva recognised reuters pharma awards europe explains several rounds treatment began promising mvppilot award feel stronger scans showed celebrates carerings potential disrupt tumours lungs sternum shrinking status quo allow contact real patients werent treatment would early stages projects activities typically takes weeks submit test werent treatment would fda approval diagnostics team came together cut time submission half retired business woman eva joseph already important test based study fda survived breast cancer nearly years approved roche test treatment followed ago returnedwith vengeance eva soon countries making test received diagnosis triplenegative breast cancer therapy combination approved triplenegative learned spread lungs sternum breast cancer globally remarkable partnership believed certain death sentence roches pharmaceuticals diagnostics terrified eva recalled learning divisions led better care patients like eva facing highly aggressive disease poor passionate spreading word prognosis thought would dead week new testing treatment options eva didnt know anyone survived stage iv cancer husband dwight also rallied support cancer research funding year people diagnosed triplenegative breast cancer worldwide want tell everyone help diagnosis means three common hope eva said help others give proteins associated breast cancer growth information gives hope people like oestrogen receptor progesterone receptor triplenegative breast cancer hopetnemeganam sevitcepsrepmanagement perspectives roche strong focus collaboration sharing knowledge lockdown measures introduced across globe meant roche find smart new ways ensure could continue research produce medicines diagnostic tests without interruption work partners keep supply chains moving hoffmann pp bbuullcckkee jj dduusscchhmmaall p frost hauser r lifton b poussot h clevers j brown schwan c franz c suessmuth dyckerhoff roche board directors december dr christoph franz chairman c e g andr hoffmann vicechairman representative shareholder group pooled voting rights c e g paul bulcke b e g dr jrg duschmal representative shareholder group pooled voting rights b e g dr patrick frost b e g anita hauser e g prof dr richard p lifton c e g bernard poussot c e g prof dr hans clevers e g julie brown b e g dr severin schwan f dr claudia suessmuth dyckerhoff e g corporate governance sustainability committee b audit committee c remuneration committee chairmansnomination committee e nonexecutive director f executive director g independent member board directors committee chairpersonchairmans shareholder letter roche dear shareholders coronavirus pandemic dominated efficacy patients severely affected world affairs like event recent history covid launched new research placed tremendous demands ussome projects working partnership others excessive reason roche levelsincluding within pharmaceutical grateful part frontline effort industrymore intensively ever overcome pandemic particular developed times crisis particular solidarity extremely reliable diagnostic tests record time cooperation keys success andthanks close trusting relationships see interview ceo severin schwan governments authoritieshave able deploy offer greatest benefit covid crisis led fewer patients seeing doctors routine checkup proud start new therapy moreover three employees around world important cancer treatments facing accomplishing difficult situation competition biosimilars usa despite given utmost dealing competition ongoing strong demand covid also done everything new medicines tecentriq cancer immunotherapy power ensure patients reliable hemlibra haemophilia ocrevus multiple supplies medicines diagnostic tests sclerosis new molecular tests led conditions types serious diseases slight sales increase chf billion simply disappear new virus ifrs net income increased swiss emerged roche employees ensured francs chf billion mainly due lower vital continuity persists despite shortage goodwill writeoffs compared previous transport capacity difficulties associated year view positive overall result consulting doctors outstanding prospects proposing dividend increase chf per share value strong infrastructure diagnostics subject approval increased substantially pandemic th consecutive dividend increase broad access molecular diagnostic tests essential controlling new recurring infectious one major reason confidence diseases tests also help prevent impressive progress made product conditions cervical cancer pipeline last year granted authorisations liver cancer due hepatitis c stateoftheart four new medicines record diagnostics make early identification prevention number new compounds registrational possible growing number diseases studies filed approval turn helps improve health outcomes boost costeffectiveness healthcare system would like mention two newly approved medicines used treat rare diseases evrysdi pharmaceuticals worked closely hereditary sma disease causes muscle health authorities test several medicines weakness enspryng major milestone unless otherwise stated growth rates report constant exchange rates cer average treatment genetic disorder increase already record level research nerve cells attacked bodys development spending immune system would like thank employees rest assured covid crisis pass exceptional commitment challenging times still plenty serious illnesses partners greatly valued cooperation roche continue combat nearly dear shareholders confidence years since founding roche repeatedly loyalty company reinvented order seize opportunities help people thanks also proactive commitment digitalisation company excellent shape future well positioned achieve medical breakthroughswell beyond coronavirusthrough outstanding scientific dr christoph franz performance end chairman board directors christoph franz visit roche diagnostics penzberg germany conversation employees informs site challenges contributions rd production logistics connection sarscov testschairmans shareholder letter roche proud employees difficult situation one thing clear none serious lifethreatening diseases simply disappears new virus christoph franz chairman board directors schwan b anderson schinecker hippe c wilbur regev w pao j h sabry b schdler c bckstiegel roche corporate executive committee december dr severin schwan ceo roche group bill anderson ceo roche pharmaceuticals dr thomas schinecker ceo roche diagnostics dr alan hippe chief financial information officer cristina wilbur chief people officer dr aviv regev head genentech research early development gred dr william pao head roche pharma research early development pred dr james h sabry global head pharma partnering barbara schdler head group communications claudia bckstiegel general counsel member enlarged corporate executive committeeinterview ceo roche group roche severin schwan coronavirus pandemic partnership suddenly become important take surprise within industry competitors yes like lot people surprised working together help fight covid pandemic grew scale companies working jointly universities less overnight pandemics hardly new research centres nothing new roche regarded phenomenon means first live pioneer field much demand difficult times coronavirus partner new though global last pandemic eitherunfortunately scale activities development data sharing production never seen anything roche fare like hugely impressed way people responded crisis developed happened make everyone join tests record time got production running forces sudden many teams working around clock urgency finding medical solution addition huge commitment also seeing realisation emerge crisis farreaching changes way work significantly faster work together become agile courageous could give us example also see effective decentralised global production capacity antibody treatments decisionmaking structures covid extremely limited take time key act quickly build roche worlds leading biotech company stepped partnering agile courageouswhat regeneron produce antibody treatment mean make available patients worldwide let give example increasing individual responsibility one concerns apart research development several years one workforce shares production else roche however easier said done partnerships large complex organisation roche pretty much everywhere actually achieve working together example working together beat coronavirus comes giving people around world access speeded process almost every day hear medicines diagnostics making sure cases people simply taken coronavirus tests end initiative acted ideas without waiting urgently needed particularly important issue green light kind thing enormous challenge see small startup companies think overcome alone fantastic also completely changing way work external partners changes goes climate change roche going lasting want reduce environmental impact half next decade looking new way work products environmental footprints stages partners outside company value creation supply chain never knowledge shared another area working closely quickly transparently including communication business partners point regulatory authorities used take obviously delighted months years takes weeks even days eleventh timebeen ranked worlds sustainable healthcare company hoping speed trust continue dow jones sustainability indices postcoronavirus era millions people benefit covid turning world upside discovered wide range antibiotics meant fight disposal thing use diseases antibiotic resistance losing sparingly especially true momentum somewhat see like recent reserve antibiotics used yes unfortunately one thing world existing antibiotics work theres one learnt pandemic simple reason fewer reserve antibiotics prepared save peoples lives use lower risk bacteria becoming costefficient long term resistant however quantities sold reserve antibiotics small something antibioticresistant bacteria already claiming needs reflected reimbursements lives every year numbers rising otherwise investment research major threat far little development worthwhile done one companies still working infectious diseases even though point pandemic end financial incentives virtually consequences roche nonexistent change pandemic thrown value diagnostics digitalisation sharp relief diagnostics exactly needs change get boost continue systematically well antibiotics revolutionised thcentury expand digital healthcare business medicine today almost century penicillin future roche group future healthcare lie let us assume minute future already reality would different imagine treatments used recent live projection building basel roche expressed months data obtained big thank part help systematically logged computer imagine covid crisis able continuously evaluate analyse immense treasure trove datain anonymised form course would able get much better view patients respond various treatments much shorter time research development medicines covid would substantially advanced stage regard realworld datapatient data routine clinical practiceas next big topic medicine data would hugely valuable covid also many diseases biggest personal takeaway pandemic lockdown gave us time reflect things truly important life family friends health course also solidarity others challenging times crisis shown us much need otherand stronger togetherinterview ceo roche group roche impressed way employees managed crisis become agile courageous severin schwan ceo roche group ever time initial outbreak pandemic little known new coronavirus patients need us deliver disease causes grateful colleagues around world stepped fight innovative medicines across pandemic ensuring continuity patient care across disease areas addressing medical multiple disease areas questions implications covid ever called upon deliver bill anderson ceo roche pharmaceuticals innovative medicines across multiple disease areas overcome unprecedented supply chain logistics hurdles help meet demands pandemic experience reminded us crucial role robust clinical trials help answer pertinent scientific questions also demonstrated importance reliable health systems encouraged parties across healthcare continuum work greater speed efficiency collaboration proven care compassion lockdown lifecorporate executive committee roche providing millions covid pandemic clearly demonstrates value importance diagnostics tests per month help fight forefront fight global healthcare crisis pandemic reduce record time developed comprehensive burden healthcare systems testing portfolio new viral disease significantly ramped manufacturing capacities providing millions tests per month help fight pandemic reduce thomas schinecker ceo roche diagnostics burden healthcare systems time able continue making substantial contributions healthcare new tests solutions cancer hiv womens health exceptional challenges demanded exceptional response intensely proud commitment resilience demonstrated across organisation agile open collaborative mindset helps us continue addressing challenges healthcare faces right patients customers finance procurement pandemic spread across globe finance procurement colleagues provided expertise helped navigate expertise needed navigate uncertainty keep company course roche finance uncertainty keep provided insights transparency record speed enabled us keep funding flowing protecting company course business continuity upholding ability invest confidence longterm research alan hippe chief financial information officer procurement colleagues partnered closely suppliers many businesscritical issues included accelerating contracting covid related actemraroactemra trials procuring timecritical blood samples essential developing covid antibody assay organisation kept business systems running people connected covid hit employees across globe shifted remote working almost overnight fared well thanks cloud platformasaservice strategy forwardthinking focused investments infrastructure dedicated people around world incredibly grateful immensely proud three groupscorporate executive committee roche shift agile way upon sensing accelerated pace unpredictable nature change began working proven especially consciously shift agile way working years ago effective year like key aspect transition embracing mindset looks every situation challenge opportunity add value patients cris wilbur chief people officer stakeholders mindset place leaders enabled people connect work selfsufficient creative networked ways driven capabilities outcomes rather hierarchy established paradigms new approach proved especially effective year like one could predicted dramatically pandemic would impact lives response colleagues across roche impressive demonstrated able make seemingly impossible possible inspired incredibly proud people special culture deep commitment purpose launched trials even joined genentech research early development august clear focus covid pneumonia matter colleagues fight pandemic learning weeks rather months covid several different phases different treatments may appropriate gred embarked early development therapeutics aviv regev head genentech research help covid patients launched early development gred several trials study impact medicines covid pneumonia trials launched matter weeks rather typical monthswithout compromising scientific rigour goal one studies covastil trial see potentially prevent progression tissue damage lung due covid infection help patients lung tissue damage recover quickly thrilled continue transformative scientific efforts seriously ill patients collaboration many great colleagues partnerscorporate executive committee roche focused maintaining addition ensuring health safety everyone pred early research much momentum possible development focused protecting lives patients trials maintaining much discovery clinical momentum possible discovery clinical portfolios continuing bring external portfolios opportunities ensuring ethical treatment animals also prioritised combating covid experts william pao head roche pharma research across pred led joined key international early development pred collaborations across industry academia internally many supported actemraroactemra trials andor scientific evaluation external opportunities regeneron collaboration agreement others pred team pitched help roche diagnostics accelerate launch timelines covid tests shared desperately needed lab supplies local hospitals enabled patients local communities receive actemraroactemra proud grateful pred employees went beyond time patients humankind need next emerge became obvious ever working together stakeholders pandemic convinced crucial combating pandemic like covid ensuring slow innovation established closer disease areas connections stakeholders working together partners scientists across organisation entered exciting across industry new collaborations signed global pandemic fight covid collaborated closely consortia james sabry global head pharma partnering authorities share broad expertise goal accelerating development potential treatments addition new partnerships gilead regeneron atea pharmaceuticals allowed us develop manufacture distribute molecules potentially treat prevent sarscov infections emerge pandemic convinced established closer connections stakeholders across industry enable us bring forward best new treatments patients futurecorporate executive committee roche one thing particularly reflecting struck sheer intensity relentless nature glad see passion transformative volatile times covid pandemic impacted everything travel roche employees pursue business daily interactions human beings mission beyond ensuring business continuity communications heavily engaged staying top global changes pandemic situation order enable smooth transition barbara schdler head group communications lockdowns also facilitated communication activities around launches sarscov tests commencement clinical trials company milestones one thing particularly glad see passion roche employees pursue mission delivering better healthcare patients many reaching communities offer help year extremes solidarity critical factor retaining validating trust placed us patients partners wider world truly strongertogether concern always took general counsel switzerland gone lockdown attention inevitably keep employees safe focused legal support companys efforts maintain business continuity healthy ensuring business roches concern always keep continuity employees safe healthy whether work home onsite businesscritical functions ensure uninterrupted manufacturing claudia bckstiegel general counsel medicines diagnostics team leveraged expertise safety health environment ensure continued supply patients muchneeded medicines every day fortunate pandemic plans place possible prepared every potential situation extent crisis required extraordinary commitment people involved wish express deep wholehearted thanks teams many roche employees worked hard make happencorporate executive committee roche celebrating years roche life core everything roche day employees partners dedicate bold science innovative diagnostics breakthrough medicines improving lives people serve year legacy promising future celebrate going really celebrating life lifein beauty complexity moments experienced shared remembered possibilities beyond horizon lifetransformed science despair hope celebrate lifedna gnitroper ygetartsreporting strategy roche transparent reporting engaging stakeholders focus developing new medicines diagnostic solutions core components business approach material topic personalised healthcare reporting approach roche committed transparent reporting endeavour drive economic social environmental performance diligence financial performance reporting scope boundaries discussed annually corporate executive financial nonfinancial reporting consists committee reviewed board directors annual report finance report effectiveness group risk management online report includes annual financial process regularly monitored group risk statements consolidated financial statements advisory team overall process reviewed nonfinancial performance indicators covers audit committee board directors regions divisions roche group well reviewed externally appropriate january december financial risk management embedded levels reporting scope defined outlined group pharmaceuticals diagnostics finance report significant divisions global functions conduct formal changes scope compared risk opportunity assessment process least year must develop response plans gri standards materiality material risks opportunities followed gri global reporting initiative g guidelines since read corporate governance transitioned gri standards using gri guidelines disclose critical also identify longterm business sustainability impacts activities environment society trends associated risks opportunities economy end conducted annual basis integrate existing first materiality analysis corporate level group risk management process year emerging conducted second global trends including associated risks opportunities materiality assessment including expert interviews identified internal external sources feedback stakeholders results assessment featured based findings corporate sustainability pages report also committee prioritises selects top business published website see link sustainability trends among trends identified healthcare evolution rising chronic risk management infectious diseases risk management policy sets roches approach identifying analysing managing un sustainable development goals reporting internal external risks support united nations sustainable opportunities consolidated group risk report development goals sdgs within sphere covers material risks opportunities corporate business strategy contribute report arrochecom rochecomarepdf rochecomfbepdf risk management rochecomriskmanagement key performance indicators rochecomperformancereporting strategy roche business sustainability trends number sdgs particularly pleased see dedicated goal health sdg healthcare evolution goal closely connected achievement healthcare evolution develops towards continuum universal health coverage goes hand hand care approach including prevention treatment cure better access quality essential medicines offering wider range solutions products services diagnostics fits perfectly vision unique opportunity accelerate delivery truly improve save lives since sdgs integrated patientcentric personalised healthcare integral part annual reporting solutions example introduced navify symptom tracker offers remote monitoring covid examples contribution un goals symptoms also developing cloudenabled integration listed un sdg webpage see link engines support digital health ecosystems mobile apps mapped material topics featured patients healthcare professionals like mysugr app monitor manage diabetes smartphone risks opportunities associated new digital health external assurance arena assessed managed group risk nonfinancial reporting verified management process pricewaterhousecoopers ag pwc independent third party pwc focused rising chronic infectious diseases materiality determination process design increasing rates chronic conditionssuch diabetes sustainability risks opportunities determination cardiovascular diseasesare putting lot pressure process figures areas safety healthcare system leading rising costs longterm security health environmental protection treatment threatening recent societal gains life people contributions since result expectancy quality addition outbreaks infectious roches strengthened control framework review diseases rise covid pandemic procedures reporting aspects figures currently experiencing demonstrated significant social related grants donations sponsorships economic impact pandemics also exacerbated healthcare patient organisations subject need work closer collaboration global institutions reasonable assurance performed pwc governments partners develop new drugs figures disclosed nonfinancial reporting innovative products encouraged us explore new key performance indicators webpage including approaches driven urgency example speed pwc assurance report drug development process see independent assurance report materiality assessment stakeholder engagement engaging stakeholders essential building trust understanding expectations embedding feedback strategy daily business able jointly address common issues develop longterm solutions order identify topics particularly institutions peers suppliers contract research relevant roche stakeholders society organisations universities investors large deliver lasting shared value also collected external internal conducted indepth stakeholder views via online survey identify corporatelevel materiality assessment among important pressing issues roche key stakeholders assessment built first address next three five years materiality analysis conducted adding external perspective gaining critical insights final step analysed various insights important stakeholders identified material topics stood learning consider emerging trends highly relevant us key stakeholders topics properly address topics aligned current goals measuring approach performance defined set indicators approach materiality assessment integratedbuilding group risk management addition materiality assessment processand inclusive designed shared internally functions charge collaboration colleagues across multiple managing respective topics assessment functions risk advisory human resources also informed discussions defining investor relations compliance finance safety new corporate goals subsequent sustainability security health environmental protection objectives communications priorities communications rolled finally outcomes materiality assessment used outcomes group risk integrated group risk management management process starting point identify process key emerging trends relevant roche group conducted qualitative interviews process results materiality experts across broad stakeholder analysis endorsed roche categories including patient organisations global corporate sustainability committee materiality rochecommateriality key performance indicators rochecomperformance contribution un sdgs rochecomunsdgsmateriality roche material topics committed delivering sustainable value stakeholders addressing following material topics commitment performance material topics supporting un sdgs innovating patients million patients treated roche sustainable healthcare systems committed developing medicines availability healthcare medicines diagnostics billion tests conducted roche affordability healthcare significantly improve peoples lives diagnostics products personalised healthcare delivering rapid broad btds breakthrough therapy designations realworld data sustainable patient access awarded fda since patient centricity products roche medicines model list rd efficiency essential medicines preparedness aging society product safety product quality trustworthy partner new partnerships pharmaceuticals human rights committed establishing diagnostics ethics transparency mutually beneficial longterm business critical suppliers audited compliance relationships partners product safety product quality cybersecurity data privacy realworld data providing great workplace key leadership roles held women talent attraction retention committed providing work employee engagement organisational agility environment employees preparedness aging society encouraged build careers pursue passions protecting environment decrease energy consumption per energy efficiency committed minimising employee since longterm mindset environmental impact operations decrease general waste per use products employee since delivering continued growth group sales longterm mindset committed creating value core operating profit continuously stakeholders sales invested rd achieving sustainable high profitability growth rates report constant exchange rates cer average strategy focus finding new medicines diagnostics establishing databased insights evolve practice medicine help patients live longer better lives business environment undergoing tremendous exceptionally broad deep understanding change facing new challenges due disease biology seamless integration complexity care increasing pressure capabilities pharmaceuticals diagnostics healthcare budgets time see new diversity approaches maximise innovation opportunities arising major advances life longterm orientation sciences digitalisation healthcare delivery create value turbulent times guided stakeholders partner choice bringing common purpose patients significant medical benefit patients doctors need next company bringing novel payers offering great place work diagnostics treatments patients nearly employees delivering sustainable positive years patients remain core contribution society earning competitive reason come returns investors work every day ultimately delivering commitments takes focus vision fitting treatments people integrity courage passion patients providing right therapy right making difference patients people patient ensure best response right proud say roche time right value approach combines rich expertise pharmaceuticals diagnostics leadership inspires outcomes matter expanded data science capabilities drive embracing diversity inclusion different effective efficient research backgrounds perspectives experiences across enable better therapeutic decisions patients entire organisation foster innovative solutions benefit patients ways working working partnership third parties enable agile networked responses ever offer integrated solutions improved medical increasing pace change balancing needs health economic benefits work many stability speed flexibility different stakeholders healthcare ecosystem broaden access offerings people setup designed innovation need ultimately provide seamless autonomous research development centres patient journey continue concentrate alliances external partners energies prescription medicines vitro foster diversity scientific approaches agility diagnostics rather diversify sectors global geographical scale reach enables like generics biosimilars overthecounter us attract talent leading global science medicines pursuit excellence science clusters quickly bring solutions people distinctiveness rests four key elements need themour strategy roche focus leadership fitting treatments patients inspiring outcomes matter distinctiveness ways working excellence science agile networked delivery setup value stakeholders built innovationgnitroppus stneitapsupporting patients roche covid severe diseases developing broad portfolio diagnostic solutions new medicineswithin roche jointly number partners across industry diagnostic solutionsthe backbone treatment decisions reliable testing contain spread covid pandemic support development effective safe medicines vaccines response ongoing public health crisis patients already infected diagnostics drawn strength virus therefore antibodies test global network across multiple sites ongoing launched partnership sd biosensor effort increase production sarscov inc south korea roche global portfolio made substantial investments distribution agreement building additional manufacturing capacity enable us increase production tests september roche launched elecsys well instruments tests antisars cov antibody test markets performed accepting ce mark targets antibodies spike protein november received february began working us fda eua test also used food drug administration fda produce quantitatively measure antibodies people coronavirus test emergency use authorization exposed sarscov play eua guidance march launched ground important part characterising vaccineinduced breaking cobas sarscov test run immune response majority current candidate widely available highvolume cobas vaccines aim induce antibody response systems molecular test received fda eua spike protein virus also available countries accepting ce mark december announced partnership less two months later received fda eua moderna inc use elecsys antisarscov highvolume elecsys antisarscov antibody antibody test modernas mrna vaccine test serology blood test specificity research trials facilitate quantitative greater sensitivity days measurement sarscov antibodies help postpcr confirmation test help assess establish correlation vaccineinduced patients immune response virus also protection levels antireceptor binding launched viewics labops covid efficiency domain antibodies improvements laboratories may also september roche received eua sarscov rapid antibody test launched fda cobas sarscov influenza ab test july intended qualitative detection igm use cobas systems test andor igg antibodies virus persons intended simultaneous qualitative detection blood serum plasma whole blood means differentiation sarscov influenza test used determine whether influenza b patients suspected havingdiagnostics roche total solutions sarscov diagnosis developed record time including molecular immunodiagnostic solutions clinical laboratory pointofcare settingsalong unparalleled rampup production capacities solutions help better contain community spread virus providing quality highvolume testing help healthcare systems respond effectively pandemic broad portfolio diagnostic solutions developed launched respiratory viral infection also available markets accepting ce mark urgent emergency care settings roche also received eua fda september cobas sarscov influenza ab test cobas liat system test provides results minutes roche also launched collaboration sd biosensor inc sarscov rapid antigen test markets accepting ce mark file eua fda first quarter sarscov rapid antigen test use symptomatic people pointofcare settings test help healthcare professionals identify sarscov infection people suspected carrying virus results typically ready minutes addition serves valuable initial screening test individuals exposed sarscovinfected patients highrisk environment december roche launched highvolume elecsys sarscov antigen test aid diagnosis sarscov infection test available countries accepting ce mark roche filed fda eua performed healthcare professionals test uses swab samples patients signs symptoms suggestive covid people either known suspected exposure sarscov changing standard care benefit patients apart sarscov tests roche introduced several important diagnostic advancements customers patients include broader test menu cobas systems currently instruments place almost twice number projected year installed indiagnostics roche advanced accurate expansion help laboratories meet global need rapidly boost testing due testing laboratories covid help increase patient access solutions drive future growth capability predict onset molecular business disease detect needs cobas epsteinbarr virus ebv bk virus bkv tests aimed transplant patients run intervention individual cobas systems first granting breakthrough device designation bdd population level tests fda approved ebv test august bkv test september fast reliable tools enable healthcare professionals monitor treat patients risk common lifethreateningconsequences ebv bkv infections transplantation solid organs andor stem cells apps algorithms three image analysis algorithms launched september first test qualitative helping pathologists deliver rapid detection hiv hiv infections accurate test results oncology upath pdl cobas systems received fda approval sp algorithm nonsmall cell lung cancer worldwide hiv infections hiv hiv diagnosis upath dual ish algorithm infections largely limited people west herpositive breast cancer diagnosis africa however hiv infections steadily increasing us europe due immigration another example cobas prime launched types virus routes us countries accepting ce mark transmission cause aids knowing first fully automatic preanalytical specific strain helps healthcare providers system prepare variety volume samples confidently treat patients effective labs receive molecular testing helps therapy guides approach monitoring reduce manual work molecular labs clinical management also september launched fdaapproved elecsys hiv duo part fight covid roche immunoassay launched decision support solution navify remote monitor enabling businesses schools fda also approved addition cintec restore operations consisting mobile app plus cytology test cobas students employees web portal systems september first triage test organisations solution collects selfreported based biomarker technology women whose risk factors displays recommendations based cervical cancer screening results positive official guidelines facilitate decisions highrisk types human papillomavirus hpv returning work school advancement help drive lifesaving revolution cervical cancer prevention treatment meeting needs todayanticipating needs tomorrow december launched cobas pikca covid already demonstrated innovative mutation test countries accepting ce mark testing helps spearhead innovative approaches patients advanced metastatic breast cancer patient care healthcare systems management test detects mutations pikca advanced accurate testing laboratories gene help clinicians identify patients may capability predict onset disease benefit targeted therapy supported detect needs intervention medical guidelines individual population level drug development pandemic despite massive disruption global pandemic commitment developing new medicines remained unbroken thanks range innovative approaches phase iii empacta study met primary development efforts became even endpoint showing patients covid effective improvement resulted associated pneumonia received actemra nine new molecules moving pivotal clinical roactemra plus standard care studies compared approximately three less likely progress mechanical ventilation per year last four years additionally death compared patients received significant increases partnering efforts placebo plus standard care provided access four latestage medicines statistical difference mortality patients four times average recent received actemraroactemra placebo years granted authorisations day study enrolled patient populations four new medicines record often underrepresented clinical studies number new compounds registrational disproportionately affected studies filed approval covid pandemic trial conducted brazil kenya mexico peru south africa us searching covid treatments early pandemic roche initiated several remdacta global phase iii randomised double approaches internal early research programme blind multicentre study initiated evaluate focused discovery medicines covid safety efficacy actemraroactemra testing roche medicines already approved plus antiviral remdesivir versus placebo plus diseases large number potential remdesivir hospitalised patients severe collaborations covid pneumonia study conducted collaboration gilead sciences inc phase iii covacta study actemraroactemra enrolment began june meet primary endpoint improved clinical status hospitalised adult patients august roche regeneron pharmaceuticals severe covidassociated pneumonia addition inc joined forces help address covid key secondary endpoints included pandemic develop manufacture distribute difference patient mortality week four regenerons investigational antibody combination met however positive trend consists two noncompeting virusneutralising time hospital discharge patients treated antibodies casirivimab imdevimab november actemraroactemra fda granted emergency use authorizationpharmaceuticals roche continued investments rd essential overcoming many devastating diseases currently without options patients approvals granted two medicines treat two rare diseases demonstrating important progress eua regenerons antibody combination inital medicines specifically tested data phase ii portion ongoing study designed treat condition today showed reduction viral load decrease condition remain untreated many medically attended visits nonhospitalised misdiagnosed importance development patients covid additional data better understood hypothetical example study expected early working think woman midthirtiesperhaps health authorities global health institutions established career starting family concerted collective response aim young children living life fullest achieving approvals begins experience symptoms nmosd prognosis becomes grim overlay october roche atea pharmaceuticals inc statistics entered partnership develop manufacture people living condition distribute ateas investigational oral frequently misdiagnosed multiple sclerosis directacting antiviral targeting covid people nmosd drove car people around globe acts blocking stopped first episode viral rna polymerase enzyme needed viral onset either stopped work needed replication currently studied phase ii reduce working hours clinical trial hospitalised patients moderate patients require wheelchair become covid phase iii clinical trial expected start functionally blind within five years first quarter explore potential use patients outside hospital setting enspryng designed chugai member roche group builds upon work conducted new medicines rare diseases cns roche develop firstinclass treatments two fda approvals offer meaningful benefits neuroimmunological diseases great example patients living rare disorders central commitment following science order nervous system cns previously limited deliver groundbreaking medicines treatment options enspryng satralizumabmwge complex difficulttotreat conditions treatment rare disorder cns years dedicated effort collaboration neuromyelitis optica spectrum disorder nmosd fda approval enspryng exemplifies patients evrysdi risdiplam people spinal industry academia work together find muscular atrophy sma solutions enspryng first subcutaneous significant breakthrough patients treatment adults living nmosd evrysdi approved treatment spinal condition primarily damages optic nerves muscular atrophy sma adults children two spinal cord causing blindness muscle weakness months age older throughout lives paralysis often misdiagnosed multiple many people sma may lose ability sclerosis recently people living nmosd perform critical physical movements sitting upright loss function impact ability independently participate aspects daily life even lifealtering without treatment around half babies type sma severe form die age two clinical studies evrysdi showed clinically today people living meaningful improvements motor function people varying ages differing levels sma nmosd remain untreated many severity including types infants achieved ability sit without support least five misdiagnosed seconds key motor milestone normallypharmaceuticals roche achievable natural course disease evrysdi also improved survival without permanent ventilation ages months compared natural history liquid medicine evrysdi administered daily home developed collaboration sma foundation ptc therapeutics evrysdi accomplishment also achieved two significant scientific breakthroughs study first placebocontrolled trial adults sma development medicine shows interfere biology deepest fundamental level targeting small molecule degree precision previously think possible expanding portfolio cancer medicines gavreto pralsetinib received fda approval treatment adults metastatic retaltered nonsmall cell lung cancer nsclc detected fdaapproved test oncedaily oral precision therapy designed selectively target victoria school student child wheelchair ill ret alterations including fusions mutations live spinal muscular atrophy retactivating fusions mutations key disease drivers many cancer types including nsclc medullary thyroid cancer treatment options selectively target genetic alterations limited nsclc ret fusions represent approximately patients administered single injection administration gavreto perfect fit personalised take approximately eight minutes initial healthcare strategy excellent example loading dose approximately five minutes practice delivering targeted cancer medicines subsequent maintenance dose based genomic alterations success gavreto compared approximately minutes demonstrates power understanding sequential infusion loading dose perjeta persons unique disease well critical role herceptin using standard intravenous nextgeneration sequencing insights like formulations minutes provided foundation medicine member subsequent maintenance infusions two roche group play achieving better outcomes medicines phesgo received fda approval treatment european commission granted conditional early metastatic herpositive breast cancer marketing authorisation polivy polatuzumab fixeddose combination perjeta herceptin vedotin combination bendamustine hyaluronidase administered subcutaneous mabtherarituxan treatment people injection used combination intravenous relapsed refractory diffuse large bcell lymphoma chemotherapy candidates haematopoietic stem cell transplant polivy represents new offtheshelf phesgo first medicine developed roche muchneeded treatment option people combines two monoclonal antibodies aggressive form lymphoma phcacross care continuum availability personalised care increases individual patients society benefit roche approach personalised healthcare however organisation achieve better phc rooted combination advanced outcomes patients society working diagnostics medicine data analytics digital alone collective effort includes patients technology goal serving providers payers policymakers regulators patients society large requires holistic biopharma companies technology companies perspective entire healthcare system enables everyone contribute unique perspective expertise experience roche instead viewing individual components confident combination deep patient care continuumprevention diagnosis scientific expertise holistic healthcare system treatment monitoringseparately roche approach close collaboration partners approaches comprehensive system across ecosystem make personalised care integrated healthcare solutions goal reality patients worldwide reduce complexity costs optimising patient societal outcomes covid pandemic wakeup call healthcare systems exposing systemic putting patient centre care gaps weaknesses time continuum establishes high bar scientific demonstrated achieved research driven data technology individual contributors join forces drive data become insights systems learn change innovation collaboratively outcomes improve lives benefit example roche partnered local service providers canada italy spain establish use data technology scientific mobile blood draw facilities providing patients research relies trust patients safe timely comprehensive genomic committed transparency integrity profiling despite breakdown healthcare data privacy practices work advance infrastructure inability local facilities inclusive research around globe ensure provide sufficient care scientific insights truly representative result new solutions address needs pandemic caused significant decrease broad diverse populations furthermore number inperson doctor visits threatening roche invested new clinical trial designs health patients managing diseases generate insights real world types including neovascular agerelated macular insights improve patient outcomes well degeneration eye disease causes severe overall care experience vision loss help ensure patients managing thescience innovation roche un sdgs material topics patient centricity rd efficiency personalised healthcare realworld data p reparedness aging society due covid regular health checks medical appointments followup treatments often declined delayed affected range disease areas including cancer diabetes diseases central nervous system diseases eye many new technologies help patients receive uninterrupted counselling safely also reducing risk exposure physicians staff especially pandemic digital pathology diabetes management ms examples conditions treated new technology disease could continue care roche partnered moorfields eye hospital united kingdom launch precommercial trial home vision monitor app patients access app smart devices safety homes test changes vision function twice weekly care team remotely monitor patients disease progression detect need clinic visits roche founding member insightthe health data research hub eye health united kingdom aims build one worlds largest data resources ophthalmology data combined advanced analytics result transform eye diseases diagnosed managed data insight already used understand impact covid patients conditions addition helping ensure patients lifethreatening chronic diseases receive uninterrupted care team roche data scientists epidemiologists created novel data analytics tool develop understanding relationship among mobility infection morbidity sarscov tool made available local hospitals testing facilities enable allocate resources effectively pandemic accelerated new era phc enabled new avenues roche put new paradigm practice today served powerful catalyst accelerating use telemedicine digital tools allow patients get care need minimising risk exposure reducing burden overloaded healthcare facilities see navify tumor boardscience innovation roche oncology partnerships lay making phc reality global partnerships groundwork personalised vision personalised healthcare measures success level improvement treatment healthcare options diverse access patient care experience includes creating adaptive learning ecosystem healthcare systems worldwide achieved collaborative partnerships based shared vision purpose australia roche partnered ministry health several clinical networks fight one aggressive types cancer clinical trial specifically designed specific form lung cancer increases patient access comprehensive genomic profiling cgp cancer applicable targeted therapy based test results trial potential improve patients prognoses also serve blueprint making personalised healthcare part clinical practice patients australia collaborates range partners across healthcare sector contributes roche belgian society medical oncology unique expertise advancement patient bsmo joined forces transform cancer care care roche invested advancing remote personalised diagnosis treatment monitoring tools needed improve disease core programme study management make timely care decisions patients solid tumours receive cgp enable efficient use resources show value cgp linked therapy access use molecular tumour boards goal research shows nearly half chemotherapy sustainably deliver better outcomes patients patients us experience unplanned emergency establishing new pathways funding department visits hospital inpatient stays innovative care cancer treatment events largely due inadequately controlled symptoms together public private sector partners side effects treatment including pain nausea roche denmark built secure virtual platform dehydration help address important encrypted anonymised data health issue roche collaborated fred hutchinson records oscar platform supports faster institute cancer outcomes research develop sustainable access personalised care digital remote monitoring system patients serves selfsustaining learning platform system potential greatly reduce healthcare system unplanned emergency visits inpatient stays enabling earlier intervention improved similar efforts canada hong kong south korea outpatient management singapore switzerland taiwan uae us several countries demonstrating roche also entered partnership harman effectiveness comprehensive interconnected international subsidiary samsung electronics solutions include testing clinical decision co ltd create digital therapeutic platform support tools physicians access right leverages virtual reality technology assist therapies innovative funding models individuals autism spectrum disorder partnership combines technology device addition publicprivate cancercare experience deep knowledge neuroscience partnerships across globe roche also effort develop innovative medicines hutchinson institute cancer outcomes research hicor fred hutchinson cancer research center httpsnewsharmancomreleasesreleases new insights developed connecting example flatiron health data used evaluate risks faced herpositive breast cancer diverse realworld datasets patients taking kadcyla specific pre existing heart problem analysis provided critical support research development insights suggested kadcyla worsen cardiac issues patients supporting optimise clinical decisionmaking product label update european union inform prescribers patients important information last years flatiron health foundation medicine partnered ambitious project combine subset data firstofitskind clinicogenomic database cgdb rapidly growing continuously updated real accelerating research development world data set serves key source datadriven data medicine offers highquality longitudinal every day data necessary optimal care clinical data combined highquality genomic patients collected creating large pool diagnostic data insights derived information known realworld data however database potential transform field data reside within individual patients new research regulatory patient records organised structured access applications facilitate new care way allows healthcare providers options discern actionable insights improve care broadly patients turning cgdb action realworld data meaningful data scale currently roche researchers leveraging key generating new insights inform novel cgdb data understand relationship transformative diagnostics therapeutics tumourgenomic features clinical outcomes tools support clinical decisionmaking across wide range tumour types clinical creating healthcare ecosystems settings insights may important continuously learn patient encounter considering targets therapeutic development specific patient populations may selectively foundation medicine flatiron health members benefit therapy choice combination roche group forefront therapy approaches additional development effort foundation medicine created opportunities given molecule genomic database flatiron health developed process curating harmonising clinical data cgdb may also serve source external electronic health records two virtual control arm tumouragnostic settings million patients result creation single drug used treat cancer largest representative deidentified types genetic mutation biomarker clinical data sets us innovative tools targeted drug certain situations insights derived scientists conducting randomised placebocontrolled trial engineers created currently includes active experimental use cancer researchers worldwide traditional control arm difficult new type external control arm used realworld data flatiron health utilised development cancer medicine rozlytrek evaluate benefitcost ratio treatment supported regulatory approval japan perjeta firstline treatment setting data helped contextualise value perjeta future information new data types treatment earlystage breast cancer another including imaging data digital pathology andscience innovation roche foundationone test helped identify mutation caused patients bladder canceran aberration typical breast cancer patients treatment combination two targeted therapies successful data wearables mobile phone apps combined clinical clinicogenomic databases yield insights help accelerate improve clinical trial programmes delivery patient care furthermore type data holds potential support access reimbursement decisions patients benefit innovative treatments sooner liquid biopsy advancing personalised care august fda approved foundationone liquid cdx foundation medicines comprehensive pantumour liquid biopsy test patients solid tumours simple blood draw test identifies circulating tumour dna cancerrelated genes allows patients advanced cancer benefit comprehensive genomic profiling insights particularly tissue biopsy possible recommended insights help physicians determine personalised treatment plan individual patient based specific mutations identified roches contributions advancing personalised healthcare show comprehensive system approach purposeful partnerships patients worldwide receive better care combined advances diagnostics medicines data digital technologies roche continues serve connector catalyst seeking purposeful partnerships across society establish integrated healthcare solutions help global health systems work better individuals healthcare providers payers society large talk patients talked jennifer genomic profiling spoke idea toolbox wanting use right treatments right time course treatment disease dr jeffrey rothenstein medical oncologist durham regional cancer centre oshawa canada read jennifers storyscience innovation roche pharmaceuticals clinical pipeline phase phase ii phase iii registration oncology inflammation immunology neuroscience infectious diseases ophthalmology metabolics others pipeline new molecular entities covers broad range diseases highly innovative technologies applied create produce active molecules accessfor everybodyworldwide pandemic proven never important urgent work closely external partners improve access medicines crucial role play supporting active member industrys stakeholders world many access accelerated initiative focused already facing budget resource constraints noncommunicable diseases ncd care need factor economic recovery low lowermiddleincome countries lmics postcovid partner city cancer challenge making significant progress building capacity lifechanging innovation medicine city level working nine cities meaningful reaches need populations one million across world goal work partnership develop tailored people roche patient access solutions create rapid broad support programmes lmics sustainable access many reasons achieved increase population innovations reach need access cancer medicines herceptin portfolio consists primarily mabtherarituxan reach almost hospitaladministered treatments often million require specialist skills infrastructure set goal increase patient access truly understand multidimensional nature breast cancer combination therapy herceptin access challenge translating plus perjeta emerging markets growing global strategy country level make sure patients understand key barriers may keep global access program hiv testing patients benefiting innovations seen fourfold increase tests run since access strategy focused four key pillars launch expanded beyond hiv include tests mycobacterium affordability tuberculosis mtb hepatitis b c hbv capacity hcv human papillomavirus hpv lmic outcomes certainty programmes value another significant priority roche measuring work across healthcare spectrumfrom impact joined forces boston governments payers ngos multilaterals university create roche monitoring insurance companies specific evaluation framework framework provides us examples show making significant progress consistent methodology evaluate social local international levels patient impact access programmes roche data file httpswwwrochecommediareleasesmedcorbhtmaccess healthcare roche un sdgs material topics ustainable healthcare systems availability healthcare affordability healthcare working collaboration global partners across healthcare spectrum enabled us increase access screening diagnosis treatment also improving capacity local healthcare systems nextgeneration medicines new diagnostic solutions represent important options patients highlight need increase access therapies working boston universitys school public health gives us objective perspective assessment tool used across world quickly understand access initiatives real impact ensure addressing right challenges understand need think differently supporting universal health coverage roche committed supporting universal health coverage uhc means patient anywhere access essential quality health services without facing financial hardship recognise uhc important vehicle addressing inequalities promoting access quality medicines see urgent need address huge inequities access healthcare around worldparticularly lmics stand ready play part advancing uhc working partnership multiple stakeholders tailored solutions create broad rapid access effort address health coverage inequality partnering stakeholders across supply chain different health service delivery points execute tailored solutions focus four key areas supporting resilient healthcare systemswe actively support governments efforts build strong resilient healthcare systems ensuring access essential medicines diagnostics roche medicines essential medicines list roche provides tests essential diagnostics list delivering tailored pricing solutionswe address affordability budget constraints different pricing models work insurers help introduce broader benefit packages protect patients particularly affected ncds assisting vulnerable groups highincome countrieswe create programmes patient support programmes enhance accessaccess healthcare roche committed ensuring responsible approach pricing committed ensuring innovations reach innovations reach patients today patients today continuing invest medical advances meet patients needs tomorrow continuing invest medical collaboration healthcare system partners use tailored pricing solutions ensure many advances meet patients needs patients possible access innovations solutions include tomorrow financebased agreements price volume cost sharing capping address concerns affordability budget uncertainty performancebased agreements utilise realworld data mitigate uncertainty benefit impact medicines payment made according level clinical health benefit achieved patientsupport programmes designed value patients limited options support patients managing outofpocket costs measurable launch several new medicines international differential pricing idp rare diseases cns approach recently updated clear demonstration benefits approach provides framework aligning prices public health system pays innovative medicines helping cure stop innovative new medicines countrys slow disease progression improve quality life relative income takes account countrys reduce medical complications avoid hospitalisations gdp well public healthcare investment reduce need surgery prevent disability uns human development index specific examples include expect ensure broader faster access dramatic reduction aidsrelated deaths due medicines countries constrained hiv treatments economies enormous developments cancer care enabling cancer patients survive evolving pricing models meet needs yearsan illness used death focus developing new pricing models sentence innovative medicines increasing models full viral hepatitis c cases differ widely country country cured health system health system know concern around whether improve alliance access covid therapies overall affordability medicines approach global pharmaceutical diagnostics companies pricing fair responsible based three issued joint statement collaboration key determinantsfirstly benefit medicine bill melinda gates foundation ensure brings patients families society secondly worlds population access covid local healthcare system reimbursement diagnostics well future vaccines medicines regulatory context thirdly allow us communiqu published september continue sustainable longterm innovation total companies including roche emphasised patients future commitment ensuring poorer countries afford products need including innovation business model built allow us donations distribution products cost continue take rd risks needed develop joint declaration life sciences companies innovative medicines tackling signed respective ceos heads complex disease areas carries high risk pharmaceuticals httpswwwwhointnewsitemwhorevealsleadingcausesofdeathanddisabilityworldwide httpswwwcancerresearchukorghealthprofessionalcancerstatisticssurvival httpswwwwhointnewsroomfactsheetsdetailhepatitisc partnerships innovative fighting hivaids roche continued support hiv solutions helping break programmes partnerships global funders also provided innovative laboratory barriers care improve patient solutions worked donors towards effective use resources order reach health outcomes areas patients places expand awareness roche partnered nonprofit organisation greatest need red emphasise importance hiv diagnostics reaching unaids goal aidsfree generation estimated year around million hiv viralload tests provided help patients monitor antiretroviral therapy eligible countries addition laboratory professionals africa received training collaboration roche scientific campus johannesburg south africa roche developed solutions specifically resource limited countries include cobas plasma separation card easytouse sample collection portfolio cervical cancer solutions automated testing device increases access remote areas platforms demonstrates commitment providing clinicians mobile health application ithemba life laboratories best tools possible protect womens health delivers hiv test results education treatment appointment reminders directly phone india roche formed privatepublic partnership focused building disease awareness improving testing quality maintaining turnaround time programme worked experts organisations clinton health access initiative chai metropolis partner national aids control programme share diagnostics expertise establishing central labs building transport partnerships increased capacity quality testing capabilities working eliminate hepatitis c virus infection egypt one highest numbers hepatitis c virus hcv infections world population infected early country launched massive effort eliminate disease nationwide screening treatment initiative roche worked egypts government officials healthcare agencies provide robust dependable hcv diagnostic see cervical canceraccess healthcare roche solutions help manage achieve ambitious goal roche provided modern diagnostic systems trained healthcare workers ensure efficiency reliability screening programmes target population million egypt screened million people one million tested positive hcv rna began treatment eliminating cervical cancer cervical cancer remains one leading causes death women august world health organization launched global strategy accelerate effort eliminate cervical cancer public health problem strategy included target vaccinate women hpv screen women aged cervical cancer provide care women diagnosed cervical cancer new recommendations policies place roche begun working multiple ngos partners deliver reliable clinically validated hpv cancer screening tools sub saharan africa working closely ministries health kenya namibia nigeria south africa change guidelines policies latin america local roche teams developed comprehensive disease management solutions support local cervical cancer programmes two examples illustrate success effort chile women screened cervical cancer resulting many cases going undetected many women developing advanced cancer roche partnered ministry health stakeholders generate valuebased evidence around use hpv screening ten centres hpv screening established healthcare professionals hcps educated primary care hcps chile women screened brazil roche worked university campinas indaiatuba municipality demonstrate value hpv screening formed basis new hpv testing guidelines rolled hcps result city increased screening women aged within months red division one campaign global movement end extreme poverty preventable diseases ministry health population egypt elzanaty associates egypt icf international egypt health issues survey cairo rockville md ministry health population icf international waked et al screening treatment programme eliminate hepatitis c egypt n engl j med mar supporting nurturing diverse inclusive working environment addressing needs diverse employee population inspiring solidarity unlocking potential people new ways work diversity inclusion covid pandemic amplified agility roche never never tolerate journey changed way work roche discrimination form embrace unique become faster flexible bolder attributes people including age gender also deepening connection purpose physical ability nationality sexual orientation special facets culture addressing culture life experience working thinking styles multiple challenges resulting pandemic capabilities preferences andor needs required high personal engagement innovation cocreation proud contributions highest level diversity refers mix achieved together several ways dealing wide range visible invisible differences unprecedented situation fostered among peopleand inclusion means making acceleration transformation novel ways mix work done proactively sensing successfully manage enormous tasks implementing initiatives create environment implemented rapidly systematically people people feel strong sense belonging constrained hierarchical boundaries treated fairly respectfully equal empowered put ideas practice access opportunities resources leveraging vast breadth capabilities contributing fully organisations success critical results immediately evident transition working home wfh made un guiding principles business within days new collaboration tools became human rights ungps identified three integral part working across roche pillars ethical humancentric business practices highly accurate sarscov tests developed protect respect remedy roche fully manufactured launched amazingly short supports implements ungps equally time frames rd efforts identified possible committed supporting covid solutions patients un sustainable development goals sdgs un global compact principles difficult time confirmed belief universal declaration human rights people greatest asset remain steadfast international labour organization declaration commitment ensuring environment fundamental principles rights work provide people nurturing diverse un global lgbti business standards roche inclusive group endorsed standards httpswwwrochecomsustainabilityapproachhumanrightshtmour people roche un sdgs material topics talent attraction retention organisational agility patient centricity roche committed ensuring environment provide nurturing diverse inclusive embrace peoples visible invisible differences support unfolding capabilities work stay step withand often ahead rapid massive transition working virtually ofcurrent di standards right also ensuring protection employees thing also prepares us way business working site customers instituting changing trends indicate safety health protocols business interactions tertiary educated workforce women others also offered roche elecsys people different ethnic backgrounds antisarscov antibody test roche millennials make workforce employees around world bringing even change way work working hard pandemic home roche view di engine innovation site significant impact peoples key success aiming wellbeing impacts range feeling reflect diverse workforce leadership isolation combating distractions come deepening global commitment di lack control work environment strive achieve representation global society home part roches global live well activities employing people wide range backgrounds special focus given health wellbeing cultures time covid additionally wide range employee assistance programmes offered part commitment great place globally including general tips wfh ergonomics work driving innovation roche dedicated mental health fitness mindfulnessresilience supporting di works accordance nutrition social wellbeing un sdg achieve gender equality empower women girls roche promotes equal roche networked organisation opportunities measures many women local regional experts already empowered reach leadership positions key step find implement localised solutions towards equality aligned local needs situations constraints eg laws regulations working global fostering safe healthy workplace network able scale apply pandemic solutions quickly covid alarm went benefited business continuity pandemicinfluenza significant adaptations made ways preparedness processes initiated working also enabled us keep making positive recent past prior planning enabled us make difference patients thanks measures managed protect business continuity sites experience massive disruptions production lines ensured continuous development delivery medicines diagnostics solutions patients tomorrows leadership committed carrying positive elements unprecedented experience ambition reflect global workforce demographics new normal ensuring health safety senior leadership translate effort employees remains top priority annual goals dynamically consider changes striving maintain healthy workplace global workforce focused two dimensions employees encouraging flexible working increasing number women key leadership positions arrangements maximum extent possible increasing number people key leadership within local legislative environment positions nationalities underrepresented regions continuing learn better building network respective experts sites empowering experts even active futureour people roche guided purpose made part local benchmark groups order exchange information share learnings significant adaptations ways best practices companies working keep making positive response covid pandemic conducted global employee opinion survey difference patients geos april goal pulse survey focused impact pandemic understand everyone roche could better support employees challenging times impressive results safety everyones responsibility rests eligible employees gave feedback levels management employee participants said felt supported result established practices reached roche came wellbeing safety goals last fiveyear period said felt proud work roche see graph occupational health safety mindset continual improvement covid pandemic significantly building path success including setting increased focus health safety series new fiveyear health safety goals unwavering ensuring employeesand feasible ambitious complete everyone work withare protected roches breakdown new goals please visit view workplaces well website thirdparty manufacturers suppliers clear categories work tasks must safe healthy order consistently fulfil commitment established safe working practices proper procedures clear employee health safety direction employees fatal contractor accident happened roche basel yet however clarified whether occupational accident feelings family victim prevention overexposure substances cornerstone protection health roches employees others handle substances define necessary measures need know potencytoxicity substance level exposure caused operation years roche assessed established levels acceptable exposure approximately substances applied systematically ensure goal exceed established standards data place ensure protection losttime illness rate roche accident rate overexposure engineering controls losttime accident rate number workrelated accidents needed new processes designed meet working days lost per year due accidents threeyear average criteria existing ones modified meet current standards containment httpswwwrochecomenvironmentourshegoalsandperformance extraordinary times people make differencethose make sure others ill coronavirus disease continue receive care tests medicines need stories spotlight remarkable contributions many outstanding employees ever rely strongertogether see everyday herosour people roche everyday heroes putting patients first flexcare transport enabled us get covid pandemic detrimental effect patients wherever doctor many patients ability receive treatment multiple care next started talking doctors efforts undertaken help ensure patients patients could continue treatment without interruption built upon idea alternative examples represent wide sites patients treated outside range efforts hospital setting lot understandable fear going hospitals lara stallardtaylor roche australia important effort country one highest populations people ms ms patients already volunteering covid treatment centre immunocompromised going hospital receive colleagues roche hungary trained ocrevus treatment actually presents higher risk doctors volunteered hungarys biggest covid becoming infected sarscov result treatment centre inspired others whatever increased risk patients electing delay ocrevus treatment delays meant patients ms would longer control levente molnar roche hungary quickly became clear alternative treatment doctors nurses grateful option needed help keep patients ms kind help could get extremely safe ensure treatment interrupted stressful times provided regular quick quickly decided develop hometreatment feedback could learn better every programme bring ocrevus infusion directly day month pulmonology patient immediately core project group centre realised could help formed significant networking medical knowledge also things collaboration programme came together learned agile transformation process quickly rather six months typically required roche past year included visualising effort project began summarising problems procedures two months solutions connecting colleagues diagnostics local doctors faith morilla edgar delasalas roche philippines many patients serve experiencing janos santha roche hungary sort disruption care really took worked hospital previously medical us aback seeing number physicians doctor different speciality altogether actually least one patient deteriorate arrived hospital two weeks levente die period werent able able highlight areas could seek care huge call action focus attention freed time team immediately jumped started specialists icu protecting environment years society come expect corporations particularly areas social responsibility transparency today stakeholder groups expect corporations inspects facilities environmental performance maximise environmental responsibility evaluates implementation policy throughout entire supply chain roche well compliance legal requirements corporate social responsibility ethical conduct internal standards team uses results business respect human rights evaluations stipulate future improvements commitment protecting environment audit pharmaceutical diagnostic top priorities many years facilities regularly review present increased risk greater frequency decades firmly believed environmental responsibility integral element standards entire supply chain good business behaviour mature environmental roche developed supplier code conduct management system ems ensures maintain hold suppliers high standards highest standards environmental responsibility responsible business ensure compliance internally across supply chain inspectors thirdparty auditors managed us examine operations relevant internal operationsprevention key suppliers necessary recommend company global production operations improvements roche exposed risks could possibly damage people goods environment reputation alignment internal standards mature ems combined professional risk established detailed performance expectations management minimises risks substantially thirdparty suppliers individual roche local sites business areas serve first line departments act first line control utilising control responsible implementing audits assessments confirm contract standards setting programmes procedures manufacturers suppliers service providers inspections selfassessments corrective meet expectations preventive actions local safety security health environmental protection officers act internal process second line advisors roche business unit managers ensuring control suppliers sits group level meet local regulations adhere defines controls audit strategy corporate standards event noncompliance may either terminate contract refuse renew request second line control lies group level improvements may actively assist audit team working specialists supplier implementingenvironment roche un sdgs material topics energy efficiency longterm mindset roche aims maximise efficient energy usage cut energy consumption increase use sustainable energy sources continuing expand global business therefore implement innovative technologies continuously upgrade infrastructure improve energy efficiency expectations suppliers clearly aim improve ecobalance communicated thoroughly enforced compared covid uncommon roche terminate collaboration pandemic well improvements decreasing partner operate responsible energy consumption air emissions well manner work minimise adverse reducing weight general chemical impacts environment waste led improvement approximately ecobalance continually minimising ecological footprint roche monitoring actively minimising last fiveyear goal period concluded environmental impact many years use end successes reaching concept ecobalance measure ecological environmental goals contributed significantly footprint resulting business activities decrease environmental footprint see system allocates points ecologically relevant graph roche stakeholders parameters eg emissions contamination resource clear companys longterm future consumption waste etc provides us committed upholding environmental global view impacting earths responsibility support commitment ecosystems measuring point totals set new series fiveyear environmental size workforce able monitor goals ambitious feasible environmental impact level complete breakdown new goals small organisational units please visit website water consumption noise pollution energy consumption roche emissions air emissions water ecobalance landfilled waste developed swiss federal office environment compliant latest guidelines httpswwwrochecomsustainabilityenvironmentourshegoalsandperformancehtmenvironment roche aim reduce emissions responsible approach energy usage sustainability source since emissions roche committed sustainable energy future made huge improvements area originate transformation recent years example increasing share renewable energy aim maximise efficient use energy focus actions energy usage cut energy consumption increase use sustainable energy sources issues surrounding energy usage continuing expand global business help us reach goal set energysaving action plans individual sites plans include implementation innovative technologies continuous upgrading infrastructure improve energy efficiency roches commitment sustainable energy even extends individual customers work help increase energy efficiency aim reduce emissions source designing diagnostic instruments utilise reducing carbon footprint purchasing energy little energy possible efficient equipment increasing sustainable energy supplies also monitoring employee converting roches suppliers renewable travel needs work processes approach energy impact since company set high expectations suppliers energy reduced ghg emissions approximately sustainability encouraging conserve natural resources even helping convert improving water stewardship sustainable energy along energy water one major commodities used pharmaceutical industry procurement organisation process around world poor water quality resulting implementing pilot project uk convert higher purification costs increased risk suppliers renewable energy sharing product contamination responsible user roches electricity rate obtained water roche upholds corporate sustainability corporate power purchase agreement offshore values contributing wellbeing wind turbine energy ask suppliers ecosystems communities operates provide us greenhouse gas protocol scope emissions converting time roche operations remain renewable energy exposed number associated risk factors allow roche measure exact carbon footprint many roches sites affected physical water reduction supply risks water stress drought well regulatory risks impact business next five years aim reduce continuity scope greenhouse gas emissions supply chain roche global procurement also one new environmental goals reduce set divisional goal increase number riskweighted water consumption per employee green suppliers next five years roche established goal combat multitude water risk factors beyond water stress track phasing greenhouse gases progress goal roche developing energy used roche comes water risk metric account burning fossil fuels releases carbon dioxide significant physical regulatory reputational greenhouse gas ghg atmosphere risk factors promoting responsible waste management commitment product stewardship demonstrates concern waste generated patients customers using products actively support responsible management waste products end life diagnostics division assembled team provide guidance relating operational waste generated production sites well liquid wastes consumables packaging resulting operation diagnostics instruments team also looks best ways decommission instruments end life examples recent guidance decommissioning include detailed information components require special handling safety environmental standpoint template contract instrument recycling vendors ensure roche requirements applied uniformly worldwide process evaluating recycling vendors ensure capable responsibly managing recovery recycling disposal processes delivering innovative tests take responsibility along pharmaceuticals division genentech stakeholders minimise impact diagnostic manages us product takeback council ptc products safety security health environment throughout partnership diagnostics division entire product life cycle diabetes care business ptc covers takeback programmes unused medicines used medical sharps lancets needles used disease management beyond regulatory compliance ptc established criteria help product teams understand key elements good better best takeback programmes guide delivering higher levels patient support products promote safe disposal sharps diabetes care participates financially supports collaborative effort pharmaceutical medical device manufacturers nonprofit actively support responsible organisation collaboration resulted significant improvements accessibility management products end quality information proper disposal patients caregivers changing behaviour life towards responsible disposal sharpsenvironment roche becoming evergreener roches environmental goals like many industries past roche come close success areas clear affiliated companies used landfills dispose sign roche takes environmental responsibility chemical solid wastes since roche seriously ever since founders set us course advocated incineration hazardous wastes greener future kept momentum suitable alternative today roche affiliates goingwith proactive mindset roche becomes ever around globe directed refrain greener performance since early sending organic chemical wastes potentially clear demonstration commitment success harmful substances landfills since reduced energy actions aim reduce environmental consumption scope approximately impact minimum committed operating per employee driven decrease energy within budget nature leaving consumption parallel decrease use behind stable living environment future fossil fuels co emissions consequently generations help make journey success decreased approximately per employee roche sites worldwide developing roadmaps period strategy clear towards sustainable energy future clear put business order first continually set monitor challenging realistic reducing energy intensity energy usage per environmental goals monitoring new employee substitute remaining environmental goals carefully energy energy generated sustainable sources strategy almost electrical power consumed roche comes sustainable sources taking approach roche positions ahead climate change scenarios published intergovernmental panel climate change looking forward roches longterm goal reduce greenhouse gas ghg emissions owned controlled sources generation purchased energy zero ghg emissions roche originate transformation use energy therefore ever since roche founders set lower ghg emissions roche opts energy efficient technology example headquarters us course greener future switzerland integrated thermal networks new buildings use rejected otherwise evergreener wasted heat fiveyear goals share sustainable energy landfilling organic chemicals tons greenhouse gas emissions tcoeq scope per employee halogenated hydrocarbons roche legacy sites tons e gn je r fg fey c en ms pu lom yep et ion general waste kgemployee water consumption memployee goal ffe fossil fuel equivalent weighted water stress changes related energy consumption terajoules total scope scope energy scope scope consumption gjemployee data collected group gj gigajouleenvironment roche coequivalent emissions tonnes scope fuel combustion halogenated hydrocarbons scope scope business flights scope direct emissions generated within facilities scope indirect emissions purchased energy scope indirect emissions included scope value chain marketbased data halogenated hydrocarbons tonnes inventory consumed released global inventory including chugai genentech ventana emissions air tonnes vocs particulates nitrogen oxides sulphur dioxide volatile organic compounds water usage discharge water withdrawn million water consumed million organic matter discharged waterways treatment heavy metals discharged waterways treatment kg landfilled incinerated waste tonnes general waste generated chemical waste generated contaminated soil construction waste less contaminated soil removed due reduced remediation activities kesslergrube germany supporting communities pandemic roche philanthropy helped communities live workand beyondface covid crisis roche long history philanthropic result people screened engagement clear strategy focus virus addition phelophepa healthcare throughout remained strongly committed staff ran mental health workshops help partners communities serve across communities cope mental stress fear four philanthropic pillars humanitarian aid anxiety stemming pandemic environment education arts emergency appeals continued fulfil commitments according united nations high commissioner supported changes focus related covid refugees unhcr kenya host fifth increased support areas could highest number refugees africa refugee largest impact years extraordinary population almost half million people conditions greatly increased importance refugees live dadaab kakuma community support also responded global camps located isolated parts appeals supported new humanitarian projects country insufficient national health system capacity covid arrived prevention first region concern safety individuals roche main external sponsor south increased considerably africas phelophepa healthcare trains years proud continue support unhcr issued global emergency appeal programme served important element funds protect refugees roche responded south africas response covid crisis donation went refugee camps trains operate partnership well urban areas hosting refugees south african ministry health transnet funds used provide range muchneeded countrys main freight logistics company materials including soap sanitisers ppe medical supplies portion donation also addition annual sponsorship roche made went improving water sanitation hygiene donation friends phelophepa facilities training rapid response teams raising employee foundation provide personal protective awareness hand hygiene setting equipment ppe sanitising equipment keep isolation centres trains healthcare workers safe possible also donated masks hygiene campaign roche also responded emergency appeals material staff use community several smaller nongovernmental organisations outreach efforts ngos making significantcommunity roche un sdgs material topics longterm mindset availability healthcare prior pandemic primary services offered phelophepa healthcare trains optical dental wellness psychology services halted order focus stopping spread virus underserved rural areas see phelophepa healthcare trains react employee foundation began new project ngo childs dream supporting quality education cambodia despite pandemic roche employees found creative safe ways keep annual tradition fundraising youth educationthe childrens walkgoing impact example foundation esther fayulu requested funding kimbondo one largest orphanages democratic republic congo support helped provide disinfection premises purchase distribution masks hygiene equipment even food infants children six months digital hardship relief students young people studying developing countries poor internet bandwidth limited access computers make online learning even challenging roche helps meet needs hundreds students around world emerging market scholarship programme one education partners fundacin educacin supports university students colombia el salvador guatemala peru organisation took challenge digital relief fund designed build technical infrastructure digitise education programmes roche contributed fund lends laptops prepaid mobile cards ensure students access online courses addition supported hardship relief fund support students struggling cover basic needs difficult times also provided hardship relief many partners included maharishi institute provides holistic university education students johannesburg south africa kiran childrens village supports higher education students poor families india roger federer foundation provided children attending early childhood development programmes malawi food information covid preventioncommunity roche remained strongly committed walk like never every year since roche employees across partners communities globe come together participate global fundraising event roche pandemicsupporting wide range childrens walk event supports roche employee action charity trust react response plans local childrens charity projects due gathering restrictions employees sites countries found creative waysranging virtual auctions walking placeto continue join forces raise money charity react partners continued supporting childrens projects crisis employee foundation also began new partnership childs dream supports children youths cambodia laos myanmar thailand fiveyear commitment helping improve access education cambodia providing quality school buildings benefit students well computer lab facilities students scholarships marginalised highschool disaster helping communities students childs dream built new school classrooms completed new rebuild computer lab facility students provided scholarships part commitment society roche philanthropy supports communities rebuilding efforts also began supporting new project significant disasters two examples days fund jakartabased ngo reduce stunting among children indonesia designed following explosion lebanon august reduce stunting well build contributed broad spectrum relief efforts across evidence best ways sustainably tackling country confirming safety employees problem ensuring immediate assistance needed contributed number emergency response secondments go digital rebuilding initiatives donated rocephin roche antibiotic global philanthropic secondment programme hospitals healthcare centres experiencing shortages allows us share company employee replaced damaged diagnostic laboratory equipment expertise ngos helping improve supported international committee red cross global health education communities around donation emergency medical supplies made donations world b education partnerships rebuild severely impacted healthcare institutions swissbased ngo promoting knowledge exchange provided support local ngos cancer funds companies europe universities africa began offering virtual career starter january australia faced unprecedented programme arranged two roche unrelenting bushfires roche made donation employeesfrom global insights digital australian red cross disaster relief recovery fund engagement people culture nigeria helped provide people living evacuation ghanato coach four recent graduates centres food water basic necessities namibia university science technology university namibia meeting high standards business ethics provide meaningful benefits society uphold high standards ethics integrity sustainability roche convinced integrity fostering culture integrity remain basis sustainable updated coc incorporated topics successful business today employees emerging interest roche stakeholders investors customers stakeholders view topics include digitalisation personalised topics ethics integrity sustainability healthcare information governance realworld increasingly vital every employee data human rights throughout roche responsibility behave integrity act conducted several activities designed inform accordance shared company values educate foster spirit key messages goes far beyond complying laws included coc month focused regulations making positive impact specific compliance topic discrimination society business endeavours harassment data privacy conflict interest activities provided information efforts include strengthening stakeholders topic variety tools including quizzes understanding ofand trust inour business infographics animations order increase respect remain independent political acceptance empower people affiliation spent chf million fostered inclusive approach activities switzerland included payments industry material cocreated affiliates across associations various chambers commerce functions reflecting diversity inclusion financial assistance trade unions donations organisation way able devise political parties cantonal federal level activities tailored addressed local needs donations political parties low addition increasing awareness understanding doubledigit thousand range swiss francs compliant business behaviour employees together accounted approximately encouraged speak potential total contributions donations violation coc might encounter share concerns multiple lines launched updated roche group managers compliance officers code conduct coc clearly defines roche group speakup line see expectations business behaviour provides box next details practical guidance clear examples coc serves business card specifies adapting policies meet changing needs commitment making valuable significant throughout covid pandemic sustainable impact society received increasing number requests deliverbusiness ethics roche un sdgs material topics human rights ethics transparency patient centricity availability healthcare compliance roche convinced integrity remain basis sustainable successful business includes safeguarding highquality supplies requiring suppliers service providers protect support human rights jointly enhancing sustainable value require business partners eg distributors suppliers service providers meet integrity standards entering business relationship perform riskbased due diligence potential partner suppliers must successfully complete due diligence process commit roches principles ethics sustainability defined supplier code conduct scoc conduct onsite audits ensure highrisk suppliers adhere scoc pay particularly close attention industries known employ vulnerable populations well highvolume suppliers suppliers highrisk locations roche updated scoc ensure alignment coc context also put greater emphasis sustainability expect suppliers help foster social environmental economic development contribute sustainability communities operate illuminating example sustainability efforts local level found medical waste recycling shanghai china china become worlds second largest medical roches biggest workforces still located san francisco device market improper medical waste basel management cause environmental pollution roche collaboration thirdparty company developed implemented innovative process safe disposal used diagnostic instruments sustainable medical waste treatment process medicines diagnostics free charge since adopted competitors donate personal protective equipment food successful collaboration roche set essential items believe find medical device industry benchmark sustainable sustainable solutions best serve patients used medical instrument disposal working alongside healthcare stakeholders another example successful local efforts comes light current global crisis added information technology many large specific guidance covidrelated requests companies outsource jobs farflung parts principles order address urgent world two roches biggest workforces questions issues unprecedented still located san francisco basel times wanted ensure could help timely created shared service centres within roche manner always maintaining compliance places like kuala lumpur budapest guidance helps understand activitiesand san jose centres run internal roche particular related fair distribution employees small key partnerships structure allocation productsare allowed still puts us better position protect human rights infringe regulations actions always subject time develop talent locally local law well internal policies countriesbusiness ethics roche suppliers commit managing risk opportunities expressly committed un sustainability principles order guiding principles business human rights enforce commitment affiliates work us suppliers worldwide roche proud part pharmaceutical supply chain initiative psci group pharmaceutical healthcare companies committed improving social health safety environmental outcomes communities time records deficiencies management suppliers located within framework systems findings related emergency exits psci roche driving force behind lack fire drills conducted development industrywide process better identify prevent violations human example illustrates partner rights environmental standards among suppliers suppliers help increase human rights standards expect suppliers comply quality truckers may forced perform standards strict principles regarding ethics jobs unsafe conditions employers working conditions environmental protection obey labour laws performed ssav health safety also require deal trucking company one major logistics risks appropriately ensure suppliers able interview employees business continuity subsupplier without management present result positive human rights supplier risk embedded throughout supplier violations found based successful pilot life cycle tailor risk management approach plan perform audits truck drivers supplier type risk present audit findings used support petition means certain highrisk suppliers assessed different companies governments various frequently countries build safe rest stops truckers regard suppliers service providers partners go beyond traditional audit concept ensure standards upheld conduct supplier sustainability assurance visits ssavs goal creating mutual trust adding value goal stands contrast conventional audits often regarded monitoring missions roche works suppliers compliance bring compliance standards attempts made bring supplier compliance supplier remains employees used roche group speakup unable meet roches minimum requirements line operated external provider available reconsider engagement supplier languages countries chief compliance officer including termination business received reports alleged violations code relationship conduct via business ethics incident reporting system unfounded founded conducted ssavs safety still investigation result employment contracts security health environment audits agreements business partners terminated worldwide main findings related excessive grounds unethical behaviour overtime andor inadequate compensation overtime ineffective maintenance employeessenisub ecnamrofrepbusiness performance roche group sales increase constant exchange rates cer decline swiss francs result continued appreciation swiss franc currenciessales chf millions roche group roche pharmaceuticals roche diagnostics puorg ehcor un sdg material topic longterm mindsetbusiness performance roche group sales rose chf medicines regular visits health practices chf billion core operating profit increased hospitals needed ie infusions many chf reflecting underlying business people continue avoid visits doctors performance core eps grew chf partly compensated additional sales ahead sales appreciation swiss franc actemraroactemra mostly due treatment almost currencies significant patients severe covidassociated adverse net impact results expressed pneumonia swiss francs compared constant exchange rates diagnostics division reported strong sales ifrs net income increased chf growth chf billion growth increase mainly due lower goodwill primarily due worldleading portfolio new writeoffs compared previous year covid tests molecular diagnostics main growth contributor driven molecular sales pharmaceuticals division decreased covid tests chf billion mainly due stronger expected biosimilars competition sales diagnostics sarscov developed covid pandemic new medicines launched year emergency testing clearly exceeded since continued strong growth covidrelated declines routine diagnostics chf billion generated sales sales additional product launches fourth chf billion thus already contributing quarter spike antibody test divisions total sales used several covid vaccine trials underlines roches speed innovation power sales new medicines grew strongly impact competition biosimilars outlook established medicines herceptin avastin despite continued strong impact biosimilars mabtherarituxan significant estimated sales expected grow low midsingle combined chf billion sales reduction digit range constant exchange rates core us europe japan earnings per share targeted grow broadly line sales constant exchange rates covid pandemic also overall negative roche expects increase dividend swiss impact divisions sales especially francs growth rates report constant exchange rates cer average topselling product portfolios chf millions scitsongaid cobas immunodiagnostics cobas virology ventana advanced staining cobas blood screening accuchek diabetes carebusiness performance roche apart sarscov tests roche growth reported emea north america latin america japan introduced several important sales decrease asiapacific driven china due decrease routine testing diagnostic advancements following severe covid pandemic restrictions customers patients addition broad new covid testing portfolio roche introduced several important diagnostic advancements customers patients include cobas prime first fully testing products sarscov rapid automatic preanalytical system prepare antigen test north america decline variety volume samples labs receive offset roche custombiotech business molecular testing three nextgeneration products solutions diagnostics biotech upath image analysis algorithms rapid manufacturers accurate test results oncology digital pathology automated analysis scans generated sales molecular diagnostics increased tissue samples strong sales growth driven segments virology predominantly sarscov roche market firsts include cobas first highthroughput pcr test launched march epsteinbarr virus ebv bk virus bkv tests lightmix systems pathogen detection panel well approved fda midyear pointofcare molecular diagnostics tests previously received breakthrough device status fast reliable tools performed diabetes care sales decreased due patients highthroughput cobas systems switching continuous glucose monitoring systems enable healthcare professionals monitor treat covid pandemic also negative impact patients risk common lifethreatening decrease reflected mainly emea consequences ebv bkv infections region demand digital diabetes management transplantation solid organs andor stem cells solutions rochediabetes care platform mysugr accuchek sugarview continued strong centralised point care solutions sales declined immunodiagnostics business tissue diagnostics sales increased due strongly impacted decline routine growth advanced staining instruments sales testing worldwide particularly china due recovery manufacturing delays prior year covid pandemic emea decline well increased sales companion diagnostics routine testing compensated partially offset lower testing volume due sales growth pointofcare covid covid pandemicslacituecamrahp incremental sales chf millions tecentriq oncology hemlibra haemophilia ocrevus neuroscience actemraroactemra immunology perjeta oncology kadcyla immunology alecensa oncology gazyvagazyvaro oncologybusiness performance roche despite massive disruption united states sales decreased result increasing competition biosimilars global pandemic commitment mabtherarituxan herceptin avastin combined partially offset sales developing new medicines remained ocrevus hemlibra tecentriq actemra roactemra ocrevus sales driven new unbroken returning patient demand partly dampened covid effects tecentriq sales increased mainly due growth new indications certain forms lung breast liver cancer europe sales grew new product sales compensating biosimilar competition herceptin mabtherarituxan avastin combined impacts perjeta first approved chf billion covid pandemic tecentriq sales continued herpositive breast cancer increased grow strongly following successful launches patient demand medicine mostly driven hemlibra ocrevus also showed strong uptake international region mainly china early breast cancer metastatic breast cancer japan sales decreased result settings considerable competition biosimilars government price cuts decline partially tecentriq first approved chf billion compensated recently launched products cancer immunotherapy various types including tecentriq hemlibra perjeta sales cancer either alone combinations ie certain grew due launch additional indication types lung bladder breast liver cancer early breast cancer strong sales growth reported regions notably us higher sales driven international region sales growth new indications extensivestage small cell lung mostly driven china russia china cancer pdlpositive triplenegative breast cancer saw strong uptake perjeta alecensa unresectable metastatic hepatocellular partially offset impact national carcinoma reimbursement drug list update covid hemlibra first approved chf billion ocrevus first approved chf billion haemophilia without factor viii relapsing primary progressive forms inhibitors prophylactic treatment multiple sclerosis shorter hour infusion administered subcutaneously weekly strong demand treatment indications every two weeks every four weeks sales continued covid pandemic continued show strong uptake especially certain negative impact us growth us europe despite covid restrictions driven new returning patients impact potential new patientsetaroproc ecnanrevogcorporate governance roche corporate governance report sets structures processes rules roche takes basis wellfunctioning corporate governance material topic compliance principles business activities focus sustainable particular applicable laws swiss stock value creation innovation management exchange six swiss exchange directives culture conforming recognised standards swiss code best practice corporate good corporate governance policy governance promulgated swiss business transparent communication embody roches federation economiesuisse companys internal corporate governance principles build governance framework particularly articles basis successful implementation roches incorporation bylaws embodies commitment serving stakeholders principles needed ensure companys businesses managed supervised manner strong board directors represents consistent good corporate governance interests shareholders including necessary checks balances stakeholders highly skilled managers act integrity extremely important printed annual report contains selected links roche website httpswwwrochecom eleventh time roche ranked readers thus provided snapshot sustainable company pharmaceuticals company reporting date also index dow jones sustainability indices directed sources consult djsi recognition based indepth time uptodate information corporate analysis economic social environmental governance roche whereas annual report performance djsi serve benchmark covers single financial year ending december investors integrate sustainability considerations website contains information portfolios sustainability core permanent nature well latest roche news business practices award reflects companys articles incorporation bylaws commitment running business way curricula vitae current former status ethical responsible creates longterm value per end term reporting date stakeholders december year least last five years members board directors corporate governance report sets corporate executive committee published structures processes rules roche website takes basis wellfunctioning corporate governance roche complies details please refer following relevant corporate governance requirements report httpswwwrochecomaboutgovernancehtmcorporate governance roche annual general meeting annual general meeting board directors board directors board committees board committees chairmansnomination committee remuneration committee audit committee corporate governance sustainability committee corporate executive committee corporate executive committee ceo ceo ceo chief financial chief people roche group pharmaceuticals diagnostics information officer officer enlarged corporate executive enlarged corporate executive committee committee gred pred partnering communications general counsel board directors due federal councils declaration dr andreas oeri prof sir john bell retired extraordinary situation based article longstanding members board directors epidemics act september dr jrg duschmal new representative pursuant ordinance measures combat shareholder group pooled voting rights coronavirus covid ordinance amendment dr patrick frost elected additional march nd annual general new members board directors term meeting agm roche holding ltd held one year march without physical participation shareholders shareholders requested addition agm elected dr christoph franz exercise rights via independent proxy andr hoffmann prof dr richard p lifton testaris ag bernard poussot members remuneration committee agm roche holding ltd march shareholders reelected dr christoph franz organising meeting immediately following chairman board directors agm board directors determined structure composition remaining furthermore agm reelected andr hoffmann committees shown see also julie brown paul bulcke prof dr hans clevers anita board directors corporate hauser prof dr richard p lifton bernard poussot executive committee dr severin schwan dr claudia suessmuth dyckerhoff members board directors roches honorary chairman dr h c fritz gerber term one year provided articles died may age years incorporation two decades shaped roches board directors board directors board committees board committees chairmansnomination committee remuneration committee audit committee corporate governance sustainability committeecorporate governance roche development leading global healthcare p lifton bernard poussot reelection company exceptionally successful dual role members remuneration committee group ceo chairman agm board directors board directors nominates testaris ag march forthcoming agm election independent proxy agm board directors nominates chairman period conclusion remaining members board directors ordinary agm shareholders reelection moreover board directors nominates dr christoph franz andr hoffmann prof dr richard composition name year birth first elected board directors dr christoph franz c e g chairman andr hoffmann representative c e g vicechairman shareholder group pooled voting rights dr jrg duschmal representative b e g shareholder group pooled voting rights julie brown b e g paul bulcke b e g prof dr hans clevers e g dr patrick frost b e g anita hauser e g prof dr richard p lifton c e g bernard poussot c e g dr severin schwan f dr claudia suessmuth dyckerhoff e g secretary dr annette luther since april board directors curricula vitae cvs members board directors current members httpswwwrochecomaboutgovernanceboardofdirectorshtm bformer members least last five years httpswwwrochecomaboutgovernanceecbodformerhtm c information cvs reporting date december year least last five years httpswwwrochecomaboutgovernancearchivformercvshtm corporate governance sustainability committee b audit committee c remuneration committee chairmansnomination committee e nonexecutive director f executive director g independent member board directors committee chairperson corporate executive committee dr gottlieb keller general counsel member effective august dr aviv regev former corporate executive committee secretary chair faculty core institute member board directors retired years member executive leadership team roche end march broad institute mit harvard well professor biology mit investigator board directors appointed claudia howard hughes medical institute joined genentech bckstiegel former head legal new head gred reports member diagnostics division position general enlarged corporate executive committee counsel april reports dr severin schwan member enlarged corporate executive committee dr severin schwan information member corporate executive committee enlarged corporate parallel dr annette luther former general executive committee listed see manager roche diagnostics international ltd also board directors rotkreuz switzerland became secretary corporate executive committee board directors reports dr christoph franz effective july dr michael varney head genentech research early development gred member enlarged corporate executive committee retired company years corporate executive committee corporate executive committee ceo ceo ceo chief financial chief people roche group pharmaceuticals diagnostics information officer officer enlarged corporate executive enlarged corporate executive committee committee gred pred partnering communications general counselcorporate governance roche composition name year birth position since corporate executive committee dr severin schwan ceo roche group bill anderson ceo roche pharmaceuticals dr thomas schinecker ceo roche diagnostics dr alan hippe chief financial information officer cristina wilbur chief people officer enlarged corporate dr aviv regev head genentech research executive committee early development gred dr william pao head roche pharma research early development pred dr james h sabry global head pharma partnering barbara schdler head group communications claudia bckstiegel general counsel secretary corporate perolof attinger executive committee statutory auditors kpmg klynveld peat marwick goerdeler sa reporting years roche holding ltd kpmg ag since auditor charge j ohn morris ian starkey mark baillache business year chief compliance officer pascale schmidt curricula vitae cvs members corporate executive committee enlarged corporate executive committee current members httpswwwrochecomaboutgovernanceexecutivecommitteehtm bformer members least five years back httpswwwrochecomaboutgovernanceecbodformerhtm c information cvs reporting date december year least last five years httpswwwrochecomaboutgovernancearchivformercvshtm group structure shareholders roches operating businesses organised shareholders related parties pages two divisions pharmaceuticals diagnostics note financial statements pharmaceuticals division comprises roche holding ltd significant shareholders two business segments roche pharmaceuticals addition significant shareholders chugai whereas genentech former published relevant webpage see link third segment integrated roche disclosure office six exchange regulation pharmaceuticals diagnostics division consists following four business areas centralised andr hoffmann vicechairman board point care solutions molecular diagnostics directors chairman remuneration committee tissue diagnostics diabetes care boards corporate governance sustainability committee member boards business activities carried group chairmansnomination committee dr jrg subsidiaries associated companies detailed duschmal member board directors information roche holding ltd significant boards audit committee serve respective subsidiaries associated companies including capacities board committees company name listing information domicile share representatives shareholder group capital equity interest listed finance pooled voting rights receive remuneration report note roche group consolidated set forth remuneration report financial statements list subsidiaries finance report note roche associates group consolidated financial statements related parties relationships exist major shareholders listed finance report shareholders pooled voting rights notes roche group consolidated financial statements equity attributable roche crossshareholdings roche pharmaceuticals incl genentech pharmaceuticals chugai centralised point care solutions molecular diagnostics diagnostics tissue diagnostics diabetes care composition six exchange regulation httpswwwseragcomenresourcesnotificationsmarketparticipantssignificantshareholdershtmlcorporate governance roche j duschmal hoffmann dr jrg duschmal member audit committee andr hoffmann chairman corporate governance sustainability committee remuneration committee capital structure information roches capital structure addition nonvoting equity securities provided finance report notes nes issued bearer form financial statements roche holding ltd form part share capital confer voting additional details contained rights nes confers rights one articles incorporation roche holding ltd share participate available earnings liquidation proceeds following repayment movement recognised amounts last share capital roches nes rights pertaining three financial years detailed finance thereto including provisions protecting report notes financial statements roche interests nes holders described holding ltd articles incorporation roche holding ltd company share capital information debt instruments chf divided fully issued outstanding bonds provided paid bearer shares nominal value chf finance report note roche group restrictions exercise consolidated financial statements debt voting rights shares upon deposit shares voted without restrictions information employee stock options provided finance report note roche authorised conditional capital group consolidated financial statements equity httpswwwrochecomaboutgovernancearticleofincorporationhtm compensation plans including detailed note roche group consolidated financial information stocksettled stock appreciation statements equity compensation plans rights ssars plan restricted stock units options issued connection debt rsus plan performance share plan psp instruments roche connect roche option plan neither options awarded employees roche issued options apart employee debt instruments issued stock options described finance report effect roches share capital board directors corporate executive committee information member board exception dr severin schwan none directors member corporate members board directors executive committee listed pages office end member members board directors age limit roches corporate executive committee restriction term office served executive capacity group subsidiary five financial years preceding curricula vitae cvs current former current reporting period members least last five years lack existing business connections bodies information including information group subsidiary independent roches board years first election additional directors independence definition based positions memberships activities available definition swiss code best practice continuously updated internet corporate governance economiesuisse addition status cvs bodies complemented specific preceding criteria relevant reporting date december least see httpswwwrochecomaboutgovernance last five years separately available boardofdirectorshtm rules pursuant article para point vegv principles governance principles number permitted activities board delegation competence reservation powers directors corporate executive committee management group companies members outlined articles executive bodies company include economic incorporation roche holding ltd environmental social topics principles together internal organisation since annual general meeting elected board directors division authority members board directors chairman responsibilities board management board directors members remits board committees remuneration committee annual basis information control mechanisms available elections nominee voted board dealings corporate management separately see articles incorporation governed bylaws roche holding ltd minutes nd annual general meeting roche holding ltd held board directors roche holding ltd march organised ensure group conducts httpswwwrochecomaboutgovernanceboardofdirectorshtm httpswwwrochecomaboutgovernanceexecutivecommitteehtm httpswwwrochecomaboutgovernancearticleofincorporationhtm httpswwwrochecomaboutgovernanceannualgeneralmeetingshtm httpswwwrochecomaboutgovernancearticleofincorporationhtmcorporate governance roche board directors board directors board committees board committees chairmansnomination committee remuneration committee audit committee corporate governance sustainability committee corporate executive committee corporate executive committee ceo ceo ceo chief financial chief people roche group pharmaceuticals diagnostics information officer officer businesses responsibly focus report operating financial risks risk longterm value creation end roche management system board delegated certain responsibilities roche group established risk several committees composition management process covering entire company chairpersons december described system place identify manage committees authorities types risks potentially affecting business responsibilities defined detail including economic environmental social bylaws board directors impacts risks opportunities stakeholder input committees chaired independent board directors highest governance directors body involved roches risk management policy sets approach accompanying according bylaws board directors responsibilities pharmaceuticals board meeting may convened without diagnostics divisions global functions conduct chairman present request formal risk assessment process least members roche board meets year year must develop risk plans assess chairmans performance meeting material risks monitored deviations attended chairman chaired reviewed regular performance dialogues vicechairman consolidated group risk report including target risk profile discussed corporate part management information system mis executive committee approved together board directors regularly informed group business plan material risks important issues sales performance etc reviewed board yearly basis board access electronic information effectiveness risk management process platform provides timely information monitored group risk advisory team board directors board committees overall process regularly reviewed system controls set forth external auditors findings presented audit committee full board board directors established system details risk management including risk controls continuously monitored factors risk management policy see audit committee corporate governance risk management website financial sustainability committee board risk management specifically described directors consists following elements finance report httpswwwrochecomaboutgovernancecommitteeshtm httpswwwrochecomaboutgovernancearticleofincorporationhtm httpswwwrochecomsustainabilityapproachriskmanagementhtm additional information provided finance report note roche group consolidated financial statements risk management system internal controls financial reporting directors report person agenda see finance report items concerning situation warrants internal audit members enlarged corporate executive group audit reports general counsel committee may also invited attend board direct access gives regular briefings committees invite chairman board audit committee corporate corporate executive committee members deliver governance sustainability committee reports committee meetings may elect ongoing activities audit reports chief commission independent expert reports call audit risk advisory executive attends audit services consultants committee partly corporate governance sustainability committee meetings year several blackout periods imposed external auditors group audit independent members board directors appraisal function evaluates reviews senior employees prohibited trading groups activities service board company stock following blackout periods directors management annual audit effect plan yearly defined focus areas eg market december february access thirdparty management validated april april senior management approved audit june july committee roche group committed october october maintaining high standard internal control blackout periods changed chairman throughout worldwide operations management board directors circumstances warrant responsible assessing business risks aspects operation implementing board directors met meetings effective efficient processes controls generally hours length including whilst ensuring compliance internal fullday meeting due covid pandemic external rules regulations board directors held several additional conducting operational audits group audit extraordinary meetings included determines managements response risks abovementioned figure planned day visit surrounding business processes systems major subsidiary board directors evaluates appropriateness completeness cancelled efficiency processes controls action plans implement necessary changes board committees met follows enhancements developed together chairmansnomination committee meetings businessauditee tracked completion approx hours statutory auditors see remuneration committee meetings approx chief compliance officer compliance officers hours subsidiaries see audit committee meetings approx hours safety health environmental protection department corporate governance sustainability corporate sustainability committee committee meetings approx hours science ethics advisory group seag issues relating genetic engineering board directors regularly conducts assessment selfassessmentassessment members corporate executive committee third parties via electronical survey personal invited attend meetings board interviews performance httpswwwrochecomsustainabilityenvironmenthtm httpswwwrochecomsustainabilityhtm httpswwwrochecomresearchanddevelopmentwhowearehowweworkethicsinrdethicalconflictshtm remuneration committee members recuse deliberations decisions matters affect interests figures indicate actual length meetings include directors extensive premeeting preparations postmeeting followup activitiescorporate governance roche members corporate executive committee maximum ordinary notice period twelve months changeofcontrol clauses employment contracts management contracts fall within scope subsection annex six directive information relating corporate governance andr hoffmann chairman corporate governance sustainability committee attendance board board committee meetings corporate governance chairmans nomination remuneration audit sustainability board committee committee committee committee number meetings c franz hoffmann j brown p bulcke h clevers j duschmal member board since march p frost member board since march hauser rp lifton b poussot schwan c suessmuth dyckerhoff j bell retired march oeri retired march member committee member since march member march remuneration shareholdings loans details regarding remuneration shareholdings rules aol loans content method determining content board cec compensation shareholding programmes rules principles basic principles elements compensation applicable performance shareholding programmes serving former related pay members board directors corporate rules principles executive committee together description allocation equity securities authorities procedure determining convertible rights options set forth separate remuneration report additional amount pages finance report payments members notes roche group consolidated executive committee financial statements equity attributable roche appointed vote shareholders related parties pages pay annual general listed note financial meeting shareholders statements roche holding ltd board rules loans credit facilities executive shareholdings postemployment benefits rules vote pay following rules remuneration shareholdings agm loans board directors board corporate executive committee cec set forth articles incorporation aoi httpswwwrochecomaboutgovernancearticleofincorporationhtmcorporate governance roche participatory rights shareholders participatory rights shareholders defined articles incorporation roches articles incorporation roche shareholders representing shares nominal shares issued bearer restrictions value least chf million request admission annual general meetings placement items agenda annual exception shares must deposited within general meeting must done later specified period date meeting days date meeting admittance card must issued shareholders name provided articles rules issue instructions incorporation shareholder elect independent proxy rules electronic represented third party annual general participation annual general meeting meeting laid corresponding invitation annual general meeting regulated articles incorporation contain restrictions articles incorporation exercise voting rights quorum requirements stipulated conformity swiss code obligations change control defensive measures articles incorporation contain provisions nonvoting equity securities would terminated mandatory bid rule swiss law applies event acquisition vesting period restrictions preexisting awards would changeofcontrol clauses removed options could exercised components remuneration based roche immediately httpswwwrochecomaboutgovernancearticleofincorporationhtm relationship statutory auditors annual general meeting roche holding ltd services agreed audit committee march shareholders voted potential nonaudit service engagement appoint kpmg ag kpmg statutory auditors reviewed policy authority proceed given based existing legal requirements swiss code obligations article auditors direct access audit concerning maximum term office seven committee chair well head group years auditor charge mark baillache audit discuss relevant issues auditorincharge since business year information long auditors reports statutory auditor auditorincharge serving consolidated financial statements capacities provided statutory financial statements found pages auditors participate audit committee meetings respectively finance report prepare written oral reports results audits audit committee oversees kpmg received following remuneration assesses auditors makes recommendations services statutory auditors roche holding board information authorities ltd auditors roche companies responsibilities audit committee see including chugai article bylaws statutory auditors participated five meetings audit committee millions chf auditing services performance kpmg assessed based auditrelated services different elements affiliate surveys assurance evaluate service level country level nonstatutory audits interviews roche key stakeholders tax services selfevaluation kpmg internal processes services ensure compliance federal audit oversight total authority faoa audit committee guide kpmgs independence ensured limiting audit fee reviewed head group audit kpmg providing certain nonaudit services approved audit committee every year furthermore permitted services exceed takes consideration changes roches total audit fee unless explicitly business well changes financial reporting rewieved approved audit committee audit standards regulations company formal policy governing engagement statutory auditor nonaudit statutory auditors elected year services limits certain permitted annual general meeting httpswwwrochecomaboutgovernancearticleofincorporationhtmcorporate governance roche auditing services provided legally required tax services include services respect compliance tax returns tax advice except auditrelated services include assurance services related audit tax accounting services provided auditors necessarily provided statutory services include advice relating process auditor services go beyond legal improvements regulations trainings requirements could include attestation services comfort letters consents consultations relationship independent proxy since testaris ag served independent meeting period proxy annual general meeting conclusion ordinary annual general march shareholders elected testaris ag meeting shareholders independent proxy period conclusion ordinary annual rules issue instructions general meeting shareholders testaris ag independent proxy rules electronic paid services annual general meeting participation annual general meeting according expenditure totalling chf laid corresponding invitation chf annual general meeting regulated articles incorporation board directors nominates testaris ag election independent proxy annual general information policy provided articles incorporation presentations analyst investor conferences corporate notices published swiss official available internet publications gazette commerce daily newspapers available designated board directors basler httpswwwrochecompublicationshtm zeitung finanz und wirtschaft lagefi le temps ordered email neue zrcher zeitung baselwarehouseservicesrochecom fax roche reports halfyear fullyear results business reports published print andor online contact address investor relations formats media events addition detailed f hoffmannla roche ltd investor relations firstquarter nine months sales figures group finance basel switzerland published year april october tel current list publication dates available fax english german internet additional information including details specific relevant information documents including contact persons available internet media releases investor updates httpswwwrochecomaboutgovernancearticleofincorporationhtm httpswwwrochecommediahtm httpswwwrochecominvestorshtm httpswwwrochecominvestorscontactshtmcorporate governance roche chief compliance officer compliance officers network chief compliance officer compliance compliance tool furthermore serves officers network committed ensuring platform ideas suggestions concerning roche group code conduct consistently documents complied throughout roche group chief compliance officer also serves contact addition roche established business ethics person shareholders employees business incident reporting beir system enables partners customers suppliers general chief compliance officer capture track public issues relating implementation monitor alleged violations initial reports compliance code local compliance officers group internal investigations department resolution employees parties become aware violations roche group code business ethics incidents recorded system conduct bring attention group internal investigations department managers supervisors local regionallocal management receives specific compliance officer report concrete information alleged violation chief compliance officer ms pascale schmidt roche group code conduct one email pascaleschmidtrochecom certain predefined categories corporate tel disclosures governance sustainability committee treated confidentially addition employees may audit committee board directors anonymously report irregularities complaints informed substantial violations managements mother tongue via speakup line case corrective actions taken questions uncertainties interpretation roche group code conduct chief compliance officer reports general reference documents employees may reach counsel also submits regular reports line managers local compliance officer corporate governance sustainability committee chief compliance officer contact needed audit committee board roche group code conduct help advice line directors nonapplicabilitynegative disclosure expressly noted information negative declaration provided six swiss contained mentioned herein either non exchange corporate governance directive applicable omission construed commentary thereto httpswwwrochecomaboutgovernancecodeofconducthtm httpswwwrochecomaboutgovernancecodeofconductcomplianceofficerhtm httpswwwrochecomaboutgovernancecodeofconducthtmnoitarenumer troperremuneration report roche performance successbased transparent market competitive remuneration important factor globally operating company like roche principles roche innovative agile company whose along performance successbased success depends substantially expertise transparent compensation structure ensure motivation performance employees compensation packages competitive conviction forms basis compensation policy structure individual components regularly benchmarked based relevant swiss european roche aims remunerate employees fairly international market criteria remuneration transparently line market conditions guidelines underlying principles also enable participate appropriately subject regular outside comparisons companys success pursue goal providing equitable competitive performance however compensation policy one factor based resultsoriented compensation safeguarding roches future success key element corporate culture offers employees strive balanced mix fixed variable conditions make best compensation components geared possible contribution shared corporate goal employees position management responsibility improving healthcare patients includes sound sustainabilityoriented value system firstly variable components intended based integrity courage passion create additional financial incentives achieve time decentralised management corporate goals keep innovation approach plays major role wide scope consistently high level increasing value individual decisionmaking respectful interactions company creates stakeholder openness diversity wideranging training groups secondly order allow employees development opportunities attractive managers participate companys business working environment unidimensional diminishment success adequate compensation measures questions remuneration would fall far key objectives incentivised annual short bonus payments longterm securitiesbased programmes roche committed fair performancebased resultsoriented compensation policy links global company like roche market employees interests various competitive remuneration plays key role stakeholder groups compensation policy httpswwwrochecomcareersforemployeesrewardshtm sound value system httpswwwrochecomcareersforemployeeslivingourvalueshtmremuneration report roche remuneration decision process approval framework overview chairman group ceo members year remuneration committee roches groups corporate executive committee must board directors decides remuneration present remuneration committee decides board members members groups corresponding compensation right corporate executive committee say decisions decision right reserved remuneration committee members remuneration decision process approval framework beneficiary remuneration board directors bod corporate executive decision approval components chairman c committee cec incl ceo roche group base payremuneration bonus c stocksettled stock remuneration committee appreciation rights ssars restricted stock units rsus annual general performance share plan psp board directors upon meeting last expired plan recommendation psp see remuneration committee last time end decisions pension c remuneration committee remuneration committee tracks market data bylaws roche board directors salaries leading global pharmaceutical articles incorporation also outlined companies major swiss companies sections principles governing reports findings full board external specific remuneration components see consulting firm pricewaterhousecoopers pwc assists remuneration committee roche end new awards granted performing market comparisons advising performance share plan psp acting pwc awarded additional mandates upon recommendations remuneration roche group information remuneration committee end board committees remit powers procedures directors determined payment last making remuneration decisions found expired psp see peer set abbott laboratories abbvie amgen astellas astrazeneca bayer bristolmyers squibb eli lilly glaxosmithkline johnson johnson merck co novartis pfizer sanofi takeda change composition peer set compared abb credit suisse lafargeholcim nestl sonova straumann swiss ubs zurich insurance change composition peer set compared httpswwwrochecomaboutgovernancearticleofincorporationhtm httpswwwrochecomaboutgovernancearticleofincorporationhtm since total aggregate amounts aktiengesellschaften vegv general meeting based decisions submitted shall vote annually binding effect general meeting approval implementing approval remuneration board ordinance excessive compensation directors resolved board directors listed jointstock companies verordnung gegen corporate executive committee details bermssige vergtungen bei brsenkotierten see abbott laboratories abbvie amgen peer set astellas astrazeneca abb bayer credit suisse bristolmyers squibb lafargeholcim eli lilly nestl roche glaxosmithkline sonova johnson johnson straumann merck co swiss novartis ubs pfizer zurich insurance sanofi takeda peer set market comparison companies salary assessment pharma peer set major swiss companies procedure submitting total board retrospective approval executive remuneration shareholder total aggregate bonus amounts corporate approval annual general meeting executive committee chairman board year annual general meeting agm directors financial year ended shareholders approve total remuneration submitted retrospectively ordinary agm board directors corporate executive separate binding approval committee decided board directors remuneration committee board directors prospective approval respectively board executive aggregate remuneration submitted prospectively according approval agm agm separate binding approval roche committed obtaining separate period two ordinary agms binding shareholder approvals total remuneration paid board directors corporate executive committee followsremuneration report roche andr hoffmann chairman remuneration committee approval total remuneration annual general meeting agm financial year financial year retrospective c bonus chairman c board directors bod bonus financial year total amount cec corporate executive committee cec including ceo roche group bonus bonus financial year total amount prospective bod base payremuneration board directors bod including chairman c aggregate total remuneration agm agm base payremuneration cec corporate executive committee cec including ceo roche group base pay aggregate total remuneration agm agm ssars base pay rsus stocksettled stock appreciation rights ssars indirect benefits restricted stock units rsus indirect benefits agm agm agm remuneration components overview remuneration elements already existing individual target value total since corporate executive committee lti corporate executive committee members enlarged corporate executive committee base pay measured january composition remuneration components year vesting expiration periods aligned longterm incentive lti changed newly issued ssars rsus see lti corporate executive committee unlike participants two programmes enlarged corporate executive members corporate executive committee committee complemented choice determining mix rsus restricted stock units rsus composed ssars fouryear ssars rsus based cliff vesting corporate executive committee lti mix ssarsrsus fixed base calculation vesting period cliff vesting expiration period based individual ssars target value total lti years years years corporate executive committee members base pay rsus measured january years years year since remaining participants ssars years gives participants additional three rsus programmes offered yearly years exercise vested ssars parallel basis choice three combinations determine vesting schedule newly issued rsus since mix restricted stock units rsus stock changed threeyear cliff vesting settled stock appreciation rights ssars options fouryear annual vesting year unlike used instead ssars countries corporate executive committee following options available enlarged corporate executive committee granted rsus vest become choice choice choice available participants vesting schedule ssars ssars ssars ssars threeyear annual vesting also rsus rsus rsus aligned fouryear annual vesting schedule new grants offering level choice empowers participants engage fully total rewards enables attractively designed roche longterm better understand critical element incentive programme enables roche attract compensation increases value motivate retain best talent keep programme aligned companys longterm success expiration period newly issued ssars since extended seven years tenremuneration report roche remuneration members board remuneration components linked directors corporate executive committee employees performance companys financial composed following elements concrete performance nonfinancial success thus composition see chart composition align interests roche employees remuneration board directors shareholders societal environmental corporate executive committee objectives also taken account fixed base salary complemented lti remuneration components intended annual variable bonus shortterm incentive sustainably homogenously longterm sti perennial remuneration elements oriented perspective align managements interest ssars rsus longterm incentive lti shareholders holders nonvoting equity securities give participating managers since end new performance share additional incentive achieve sustainable plan psp awards granted acting shareholder value growth upon recommendations remuneration committee end board directors determined payment last expired psp composition remuneration board directors corporate executive committee annual remuneration elements description c bod ceo roche group cec base pay monthly payment q uarterly remuneration see payments bonus annual payment f years f years cash see blocked nonvoting blocked nonvoting equity securities equity securities andor shares andor shares pensions etc see perennial remuneration elements stocksettled stock see f years appreciation rights additionally ssars blocked nonvoting equity securities exercise restricted stock see f years units rsus blocked nonvoting equity securities performance share see f years plan psp blocked nonvoting last expired plan equity securities psp andor shares fixed base salary indirect benefits employer contribution pensions insurance contributions sti roche roche connect bonus remuneration tax consulting services lti components expense allowances stocksettled stock appreciation rights restricted stock units others performance share plan childrens schooling costs foreign tax obligation variable longterm ahvivalv employer contribution social securities beneficial parts base pay fixed rates operating profit capital charge opac base pay cash payment determined based core operating profit core earnings per position based salary market data leading share nonvoting equity security nes growth global pharmaceutical companies see footnote constant exchange rates product development major swiss companies see footnote pipeline diversity employees managers reflects individuals abilities experience environmental goals additionally linked performance time pay adjustments achievement measurable qualitative likewise linked individual performance take individual functional performance objectives account prevailing market conditions competitive reasons roche disclose companys overall financial situation individual performance objectives members corporate executive committee remuneration committee makes reviews chairman final decision individual base pay paid chairman board directors members december end reporting year corporate executive committee january following reporting year remuneration remuneration members board committee decides bonuses amounts payable chairman board bonuses variable members corporate executive committee bonuses annually awarded individual respect relevant reporting year based contributions value creation business year performance aforementioned objectives meant incentive strive outstanding time remuneration committee results create new business opportunities also decides form bonuses awarded bonus amounts linked group divisional ie cash payments andor blocked applicable core profits sales growth constant exchange nonvoting equity securities andor sharesremuneration report roche remuneration committee uses discretion defined fouryear vesting period plus value appropriately weighting criteria adjustment amount equivalent bonus allocation sum dividend paid vesting period attributable number nonvoting equity total around employees securities andor shares individual eligible bonus roche bonus program award granted vested recipient corporate executive committee stocksettled stock appreciation rights four years thereafter resulting nonvoting ssars longterm equity securities andor shares may remain blocked since ssars proportion lti ten years corporate executive committee based individual target value total rsus served remuneration component lti corporate executive committee members eligible roche employees base pay measured january year performance share plan psp longterm psp established periods ssars entitle holders benefit financially three years based threeyear increase value roches nonvoting equity comparison total shareholder return tsr securities grant date exercise peer companies see footnote plans date since ssars granted vest together key performance metric award tsr four years exercised within calculated threemonth moving average ten years grant date unexercised ssars rate start end lapse without compensation since fair performance cycle value ssars calculated grant date using trinomial model american call new psp awards granted since options details see end therefore one performance cycle psp left ssars corporate executive committee closed december allocated individually remuneration board directors discretion acting committees discretion upon recommendations remuneration committee determined payment end total employees received ssars see restricted stock units rsus longterm indirect benefits proportion restricted stock units shown ceo roche group rsus members corporate executive chairman respectively members committee total lti based corporate executive committee additionally individual target value total lti corporate received indirect benefits payments pension executive committee members funds insurances roche connect payments base pay measured january year rsu foreign tax obligation tax consulting services awards allocated individually corporate annual expense allowances shown executive committee remuneration individual members corporate executive committees discretion committee received payments family children education allowances schooling costs rsus contain rights receive nonvoting equity children securities andor shares since newly weighting fixedvariable longterm remuneration components target percentage total remuneration chairman board directors corporate executive committee including ceo roche group fixed variable longterm variable longterm remuneration paid members corporate executive committee ranged fixed compensation ratio variable remuneration components relative fixed base pay corporate executive committee ratio variable remuneration components bonuses ssars rsus relative value fixed base pay lti longterm sti variable total criteria bonus ssars total lti rsus total lti individual target value minimum maximum performance criteria group objectives group divisional business value development value development performance individual objectives considering determined determined core profits sales growth constant exchange performance nes performance plus rates operating profit capital charge opac grant value adjustment based core operating profit core earnings per dividends nes share nonvoting equity security nes growth grant constant exchange rates product development pipeline diversity employees managers environmental goals split group objectives na na b individual objectives na na weighting criteria remuneration committees discretion decision objectives na applicable assessed consideration performance competitors macroeconomic development based already existing individual target value total lti corporate executive committee members base pay measured january year details please refer following sections remuneration report see also finance report note roche group consolidated financial statements related parties note financial statements roche holding ltd board executive shareholdings remuneration board directors resolution approval directors table board remuneration chairman board activities roche paid legally required employers directors members board directors contributions totalling chf swiss social decided remuneration committees security programmes providing retirement disability discretion taking account market comparisons unemployment benefits ahvivalv members board directors beside legally remuneration form cash payments required contributions separately stated annually tracked market data chairman board directors directors pay leading global pharmaceutical companies see footnote major swiss basic remuneration board directors companies see footnote assisted excluding chairman remained unchanged consultancy pwc since previous years board exception chairman board directors separately submit total aggregate directors bonus form blocked shares bonus chairman board directors dr severin schwan executive member general meeting financial year board members board directors retrospective binding approval awarded shares nonvoting equity securities ssars maximum amounts total aggregate remuneration board directors period loans credits granted members ordinary general meeting board directors ordinary general meeting separately tabled previous years capacity member chugai general meetings prospective binding approval international council cic chugai pharmaceutical see co ltd andr hoffmann received honoraria amounting total usd chf amount remuneration members board directors advisory service genentech members board directors scientific resource board prof dr richard p lifton received remuneration additional compensation received honoraria amounting total form quarterly fixed cash payments usd chf prof hans clevers shown remuneration members board usd chf respectively list members positions committee memberships chairmanships see detidua remuneration report roche remuneration members board directors chf additional remuneration additional special basic remuneration committee memberschairs remuneration total remuneration c franz chairman see total remuneration paid chairman board directors hoffmann vicechairman see j brown p bulcke h clevers see j duschmal since march p frost since march hauser rp lifton see b poussot schwan see highest total remuneration paid dr severin schwan member corporate executive committee remuneration received primary function ceo roche group reflected total remuneration corporate executive committee c suessmuth dyckerhoff j bell march oeri march total exception members chairmans committee chairman vicechairman board members receive chf year committee serve chf year committee chair remuneration serving vicechairman board prorated remuneration period march december prorated remuneration period january march additionally employer contribution ahvivalv totalling chf including chairman paid form part remuneration detidua remuneration members board directors chf additional remuneration additional special basic remuneration committee memberschairs remuneration total remuneration c franz chairman see total remuneration paid chairman board directors hoffmann vicechairman j bell j brown p bulcke h clevers since march hauser rp lifton oeri b poussot schwan see highest total remuneration paid dr severin schwan member corporate executive committee remuneration received primary function ceo roche group reflected total remuneration corporate executive committee c suessmuth dyckerhoff pr voser end june total exception members chairmans committee chairman vicechairman board members receive chf year committee serve chf year committee chair remuneration serving vicechairman board prorated remuneration period march december prorated remuneration period january end june additionally employer contribution ahvivalv totalling chf including chairman paid form part remuneration total remuneration paid chairman form shares blocked ten years payable board directors march put shareholder binding vote chairman dr christoph franz received total ordinary annual general meeting agm remuneration shown remuneration committees bonus proposal adopted chairmans total remuneration contained late respect financial year total remuneration board directors total remuneration paid chairman board directors chf base salary cash bonus subject approval annual general meeting pension fundsinsurancesannual expense allowances including employer contribution social securities beneficial parts total form shares blocked years calculation number shares based price date transfer march respectively approval agm agm respectively calculation value consideration reduction value due blocking period years reduced market value submitted shareholder approval agm approved agm respectively agreed reduction pension fund contributions upon reaching age dditionally employer contribution ahvivalv chf chf paid form part remuneration detidua detidua remuneration report roche total remuneration paid board board remuneration subject approval directors annual general meeting calendar year members board directors received remuneration submission chairmans total including bonuses employer contribution aggregate bonus binding vote social securities beneficial parts totalling annual general meeting chf chf excluding remuneration chairman board additional employers contribution paid ahviv directors includes bonus award chf alv totalling chf chf form shares blocked ten years shown form part remuneration table section total remuneration paid chairman board directors remuneration paid former members board directors submit remuneration board directors committees bonus proposal adopted late former member board directors dr franz b chairman board dr christoph franz humer received fees amounting total respect financial year payable usd chf serving member march excluding legally required employers chugai international council cic chugai contributions ahvivalv shareholder pharmaceutical co ltd binding vote ordinary annual general meeting former member board directors william burns received honoraria amounting total usd chf capacity member chugai international council cic chugai pharmaceutical co ltd additional remuneration paid retrospective approvals chairmans total aggregate bonus chf proposal agm agm agm aggregate amount aggregate amount aggregate amount financial year financial year financial year total aggregate amount proposal approval approved agm excluding legally required employers contributions ahvivalv bonus award form shares blocked years calculation number shares based price date transfer march march march respectively approval agm agm agm respectively calculation value consideration reduction value due blocking period years reduced market value submitted shareholder approval agm approved agm agm respectively detidua remuneration report roche submission boards total aggregate dr severin schwans remuneration shown future remuneration binding shareholder receives function ceo vote roche group member corporate board directors proposes executive committee included ordinary agm approve board remuneration totalling part corporate executive committees chf excluding legally total remuneration required employers contributions ahvivalv excluding bonuses period ending ordinary agm prospective approvals boards total aggregate future remuneration chf proposal agm agm agm aggregate amount aggregate amount aggregate amount period period period agm agm agm agm agm agm total aggregate amount proposal approval approved agm excluding legally required employers contributions ahvivalv excluding bonuses reconciliation reported excluding bonuses period ending remuneration shareholders approved ordinary agm remuneration members board directors comparison ordinary agm ordinary agm approved board ordinary agm actual remuneration remuneration totalling amounted chf excluding legally chf excluding legally required required employers contributions ahvivalv employers contributions ahvivalv excluding bonuses prospectively approved total remuneration members board directors comparison actual total payments made chf total remuneration total remuneration total remuneration period period period agm agm agm agm agm agm maximum total remuneration approved agm actual total remuneration paid calculation end period within approved limit calculation end period yes yes excluding legally required employers contributions ahvivalv excluding bonuses security holdings statements related parties directors andr hoffmann dr jrg duschmal note financial statements roche members founders families holding ltd significant shareholders closely associated belong addition december contractually bound shareholder group december respectively members pooled voting rights end board directors persons closely group held shares issued associated held roche shares shares detailed information group nonvoting equity securities nes american found finance report note depositary receipts adrs shown roche group consolidated financial table security holdings security holdings shares nes december december nonvoting nonvoting close equity close relatives equity relatives securities security others securities security others shares nes holdings number shares nes holdings number number number numbertype type number number numbertype type board directors c franz hoffmann j brown p bulcke h clevers j duschmal na na na na p frost na na na na hauser nes nes rp lifton adrs adrs b poussot schwan see security holdings see security holdings corporate executive committee corporate executive committee c suessmuth dyckerhoff total nes adrs nes adrs na applicable shares held shareholder group pooled voting rights listed jointly held close relative r oches adr american depositary receipt listed otcqx httpswwwotcmarketscomstockrhhbyquote international premier symbol rhhby isin us traded usd eight adrs represent one underlying nesremuneration report roche remuneration corporate executive committee resolution approval amount remuneration members remuneration members corporate corporate executive committee executive committee decided general provisions assigning authority remuneration committees discretion taking decisions corporate executive committee account market comparisons remuneration remuneration committee board directors outlined previous years board remuneration decision process approval directors separately submit total aggregate framework bonuses corporate executive committee general meeting financial year members corporate executive retrospective binding approval committee received remuneration work shown amount remuneration maximum amounts total aggregate ceo roche group dr severin schwan remuneration corporate executive committee explained detail period ordinary general meeting ordinary general meeting payments dr gottlieb keller retired tabled previous years corporate executive committee general meetings prospective binding approval roche end march see included aggregated total remuneration corporate executive committee see highest total remuneration paid highest total remuneration paid member dr severin schwan member corporate executive committee see corporate executive committee included total amount paid corporate dr severin schwan executive member board executive committee see total remuneration directors received remuneration primary paid members corporate executive function ceo roche group reflected committee highest total remuneration paid dr severin schwan member corporate executive committee chf base salary bonus subject approval total aggregate bonuses corporate executive committee annual general meeting ssars rsus roche connect pension fundsinsurances payments incl expense allowancefor tax consulting services total light overall economic impact corona pandemic dr severin schwan waived amount chf contractual base salary detailed calculation remuneration see annual report shares blocked years calculation number shares based share price date transfer march approval agm sars number grant value according trinomial model american call options chf trinomial model american call options value described stocksettled stock appreciation rights ssars members corporate executive committee ssars blocked years may thereafter exercised whilst exercising resulting nes automatically blocked additional years calculation value nonvoting equity securities consideration reduction value due additional blocking period years reduced market value ssars number grant value according trinomial model american call options chf trinomial model american call options value described stocksettled stock appreciation rights ssars members corporate executive committee ssars blocked years may thereafter exercised whilst exercising resulting nes automatically blocked additional years calculation value nonvoting equity securities consideration reduction value due additional blocking period years reduced market value calculation rsus value number rsus multiplied grant value chf nes closing price grant date march per rsu calculation rsus value number rsus multiplied grant value chf nes closing price grant date march per rsu includes annual expense allowance chf payments tax consulting services chf chf family children education allowance chf chf additionally employer contribution ahvivalv chf chf paid form part remuneration calculation value nonvoting equity securitiesshares consideration reduction value due blocking period years reduced market value including employer contribution social securities beneficial parts detidua base pay members corporate executive committee base pay chf b anderson hippe schinecker c wilbur total base pay dr gottlieb keller retirement bonus chf proposed roche end march included included aggregated total remuneration aggregated total remuneration corporate executive committee see corporate executive committee see total aggregate amount bonuses brought forward binding vote annual bonuses members general meeting corporate executive committee remuneration committee board except dr severin schwan members directors determined corporate executive corporate executive committee receive committee members bonuses based bonus cash payment dr severin performance agreed objectives schwan receive bonus form roche remuneration committee uses discretion shares blocked ten years see appropriately weighting criteria bonus payment due march bonus allocation dr gottlieb keller bonus chf subject approval total aggregate bonuses corporate executive committee annual general meeting b anderson hippe schinecker c wilbur total detidua detidua remuneration report roche stocksettled stock appreciation rights total lti corporate executive committee ssars members corporate members base pay measured executive committee january year ssars corporate executive committee allocated individually remuneration fair value ssars calculated grant committees discretion ssars shown date using trinomial model american call ssars table entitle holders options trinomial model effective method benefit financially increase value valuation american call options considers roches nonvoting equity securities nes possibility exercising option time prior grant date exercise date strike price maturity called american option compared ssars terms multiyear plan european option allows exercise closing price roche nes grant date maturity date ssars since vest four previously granted ssars three years grant date vested numbers ssars strike prices expiry ssars exercised converted nes within dates grant values ssars shown ten previously granted ssars within seven years ssars table grant date unexercised ssars lapse without numbers ssars calculated time issue compensation entered values table since ssars proportion lti corporate executive committee based ssars granted dr gottlieb already existing individual target value keller restricted stock units rsus individually corporate executive committee members corporate executive remuneration committees discretion committee since proportion restricted stock units rsus contain rights receive nonvoting equity rsus members corporate executive securities andor shares since newly committee composed total lti defined fouryear vesting period plus value based already existing individual target value adjustment amount equivalent total lti corporate executive committee sum dividend paid vesting period members base pay measured attributable number nonvoting equity january year rsu awards allocated securities andor shares individual information trinomial model american call options please refer boyle phelim p lattice framework option pricing two state variables journal financial quantitative analysis volume issue mar httpswwwrochecomdamjcraaacbfa bcbeacentrinomialmodelpdf detidua stocksettled stock appreciation rights ssars grant value per grant value per number ssar chf value chf number ssar chf value chf b anderson hippe schinecker c wilbur total price chf expiry date price chf expiry date performance share plan psp committee determined payment end members corporate executive committee psp established periods provisions plan number three years based threeyear nonvoting equity securities nes shares comparison total shareholder return tsr reserved participants cycle peer companies see footnote plans number securities actually awarded depend key performance metric award tsr whether extent investment roche calculated threemonth moving average securities shares nes outperforms average rate start end return investment securities issued set performance cycle peer companies see footnote comparisons based securities market prices dividend new psp awards granted since yields ie total shareholder return tsr end therefore reduce effect shortterm market fluctuations one performance cycle psp left security prices averaged three months closed december october december prior start board directors discretion acting performance cycle three months upon recommendations remuneration october december end cycle detidua remuneration report roche award granted vested dr gottlieb keller received rsu awards recipient corporate executive committee four years thereafter resulting nonvoting equity securities andor shares may remain blocked ten years restricted stock units rsus value grant value grant number chf value chf number chf value chf b anderson hippe schinecker c wilbur total calculation value consideration reduction value due additional blocking period years reduced market value calculation value consideration reduction value due additional blocking period years reduced market value detidua roche securities perform better average indirect benefits members peer set board directors elect corporate executive committee increase nes shares award maximum employer contributions made social award double originallevel reserved target security schemes pension plans groupwide number nes shares according psp plus employee stock purchase plan roche connect value adjustment amount equivalent respect members corporate executive sum dividend paid vesting committee shown indirect benefits period attributable number nonvoting employer contributions table equity securities shares individual table award granted requires roche securities perform well better roche connect voluntary stock purchase peer set event investment plan offering employees opportunity buy roche securities underperforms average roche nonvoting equity securities nes return delivered peer companies fewer amount equal annual salary nes shares awarded discount nes purchased plan subject holding period four years end psp cycle based switzerland threemonth average distributed dividends totalling chf billion chf billion addition members corporate executive chf billion chf billion committee received annual expense allowances according terms plan participants members payments foreign tax received originally targeted nes obligations tax consulting services shown awarded end psp cycle table nes originally targeted nes incl nes group ceo outlined pages payments employer contributions indirect annual report taking benefits dr gottlieb keller retirement account retired members corporate roche end march included executive committee awarded aggregated total remuneration corporate executive committee see bill anderson dr thomas schinecker participating psp programme indirect benefits employer contributions chf payments payments annual taxtax annual taxtax pension funds expense roche consulting pension funds expense roche consulting insurances allowances connect services insurances allowances connect services b anderson hippe schinecker c wilbur total including employer contribution social securities beneficial partsdetidua detidua detidua remuneration report roche remuneration loans members contribution social securities beneficial parts corporate executive committee payments dr gottlieb keller meet legal contractual obligations retirement end march totalling roche paid total chf individual chf excluding members corporate executive committee additional employers contribution paid ahviv family child education allowances alv totalling chf chf childrens schooling costs form part remuneration aforementioned additional payments additional remuneration included total remuneration members abovementioned payments paid current corporate executive committee former members corporate executive committee loans credits granted members corporate executive committee executive remuneration subject approval annual general meeting maximum regular period notice members corporate executive committee months submission executive total aggregate changeofcontrol clauses bonuses binding vote annual employment contracts general meeting board directors proposes awarding remuneration former members members corporate executive committee corporate executive committee bonuses dr severin schwan form roche additional remuneration shares blocked ten years abovementioned payments paid former members corporate executive committee members corporate executive committee cash payment see totalling chf respect financial total remuneration paid members year chf excluding legally corporate executive committee required employers contributions ahvivalv calendar year members submit proposed total amount corporate executive committee received ordinary annual general meeting agm remuneration including bonuses employer binding vote retrospective approvals members executive committees total aggregate bonuses chf proposal agm agm agm aggregate amount aggregate amount aggregate amount financial year financial year financial year total aggregate amount proposal approval approved agm excluding legally required employers contributions ahvivalv submission executive total future incentives ssars calculated grant value aggregate remuneration binding without considering reductions value due shareholder vote blocking periods applicable rsus see board directors proposes calculated time reservation nonvoting ordinary agm approve remuneration equity securities shares without considering corporate executive committee totalling reductions value due blocking periods chf excluding legally contributions pension benefits excluding legally required employers contributions ahvivalv required employers contributions ahvivalv excluding bonuses period ending well contributions expenses payments ordinary agm foreign tax obligations tax consulting services roche connect amount executive total future aggregate remuneration composed base pay longterm prospective approvals members executive committees total future aggregate remuneration chf proposal agm agm agm aggregate amount aggregate amount aggregate amount period period period agm agm agm agm agm agm total aggregate amount proposal approval approved agm excluding legally required employers contributions ahvivalv excluding bonuses reconciliation reported excluding bonuses period ending remuneration shareholders ordinary agm prospectively approved remuneration members corporate executive comparison ordinary agm committee ordinary agm remuneration amounted ordinary agm approved remuneration chf excluding legally required corporate executive committee totalling employers contributions ahvivalv chf excluding legally excluding bonuses psp assumption maximum required employers contributions ahvivalv valueremuneration report roche prospectively approved total remuneration members executive committee comparison actual total remuneration effected chf amount period amount period amount period agm agm agm agm agm agm maximum total remuneration prospectively approved agm total remuneration calculated end calculation end corresponding agmagm period period agm agm actual total remuneration realised corresponding agmagm period based calculated calculated actual amount calculated retrospectively end period end psp cycle end corresponding psp cycleas calculation end agm agm grant value rsus period agm agm within approved limit calculation end period yes yes additional amount paid new members corporate executive committee approval agm within approved total amount excluding legally required employers contributions ahvivalv excluding bonuses including assumption amount maximum possible award sharesnonvoting equity securities corresponding psp cycle r esulting amount due award originally targeted nes psp cycle clawback activity leading serious disciplinary action addition applicable statutory provisions repeated willful failure perform duties roches longterm incentive plans include reasonably assigned roche option partially reclaim distributed compensation violation law public regulation result special circumstances clawback commission crime gross negligence willful misconduct employee voluntarily serves notice employment termination employment ssars see engaging conduct bringing disgrace disrepute rsus see unvested date roche andor subsidiaries termination employment lapse immediately violation roches directives guidelines without compensation relating business conduct upon termination employment result serious according regulations psp programme misconduct ssars rsus granted originally targeted awarded nes outstanding whether vested unvested shall lapse shares shall lapse without compensation upon immediately without compensation according notice termination employment given ssars plan rules serious misconduct reason redundancy disability participant may include inter alia retirement guidelines security holdings holdings long serve board directors decided corporate executive committee exception ceo roche group members bill anderson dr thomas schinecker corporate executive committee must acquire joined corporate executive committee shares andor nes equivalent two annual base must fulfil requirement end salaries ceo roche group since equivalent members corporate executive five annual base salaries one annual base committee fulfil requirement salary respectively end retain type security value acquired ceo roche group shares andor nes annual base salary members corporate executive committee shares andor nes annual base salary security holdings associated held securities shown december december following tables shares nonvoting equity respectively members corporate securities nes ssars restricted stock executive committee persons closely units rsus shares nonvoting equity securities nes december december close relatives close relatives shares nes security holdings shares nes security holdings number number numbertype number number numbertype corporate executive committee shares nes shares nes schwan b anderson hippe schinecker c wilbur total remuneration report roche ssars number ssars held december corporate executive committee schwan b anderson hippe schinecker ca wilbur total price chf market price per nes december chf expiry date grant value per ssar chf since trinomial model american call options values according corresponding annual reports restricted stock units rsus number rsus held december corporate executive committee schwan na b anderson hippe na schinecker c wilbur na total grant value per rsu chf chf chf nes closing price grant date nes closing price grant date nes closing price grant date march march march na applicablestatutory auditors report roche general meeting roche holding ltd basel audited accompanying assurance whether remuneration remuneration report roche holding ltd report complies swiss law articles year ended december ordinance audit limited information according articles ordinance audit involves performing procedures excessive compensation listed jointstock obtain audit evidence disclosures made companies ordinance contained remuneration report regard sections marked audited grey line compensation loans credits accordance including respective footnotes pages articles ordinance remuneration report procedures selected depend auditors judgement including assessment risks responsibility board directors material misstatements remuneration board directors responsible report whether due fraud error audit preparation overall fair presentation also includes evaluating reasonableness remuneration report accordance swiss methods applied value components law ordinance board directors remuneration well assessing overall also responsible designing remuneration presentation remuneration report system defining individual remuneration packages believe audit evidence obtained sufficient appropriate provide auditors responsibility basis opinion responsibility express opinion accompanying remuneration report opinion conducted audit accordance swiss opinion remuneration report auditing standards standards require year ended december roche holding comply ethical requirements ltd complies swiss law articles plan perform audit obtain reasonable ordinance kpmg ag mark baillache marc ziegler licensed audit expert licensed audit expert auditor charge basel february kpmg ag viaduktstrasse po box ch basel kpmg ag subsidiary kpmg holding ag member kpmg network independent firms affiliated kpmg international cooperative kpmg international swiss legal entity rights reserved independent limited assurance report nonfinancial reporting corporate governance sustainability committee roche holding ag basel engaged perform assurance figures roche group level relation procedures provide assurance aspects payments donations disclosed nonfinancial reporting roche report holding ag basel consolidated subsidiaries management reporting processes roche included annual report respect payments donations report contributions key figures well related control environment relation data scope subject matter aggregation key figures assurance engagement relates limited level assurance focused data information criteria year ended december disclosed management reporting processes respect report roche nonfinancial reporting key figures prepared roche based policies carried work data reported procedures set forth following prior reporting periods respect roche group guideline grants donations projections targets sponsorship gsd data collection process disclosed website following specified data information roche group internal nonfinancial reporting published report within scope guidelines based responsible care limited assurance engagement health safety environmental protection materiality determination process roche reporting guidelines published european group level according requirements chemical industry council cefic gri standards disclosed gri standards published october report global reporting initiative gri design sustainability risks roche group internal corporate reporting opportunities determination process based manual sustainability reporting guidance roche group level activities disclosed economic performance issued march paragraph risk management roche materiality determination process report group level based gri standards safety security health environmental published october global reporting protection key figures including initiative gri greenhouse gas emissions scope defined guidelines payments scope resulting business flights donations contributions key figures tables graphs sustainability risks opportunities internally report gathered collated aggregated pricewaterhousecoopers ag birchstrasse postfach ch zurich telephone telefax wwwpwcch pricewaterhousecoopers ag member global pricewaterhousecoopers network firms separate independent legal entityindependent limited assurance report roche inherent limitations requirements professional standards accuracy completeness nonfinancial applicable legal regulatory requirements indicators subject inherent limitations given nature methods determining responsibility calculating estimating data ghg responsibility perform limited assurance quantification subject inherent uncertainty engagement express conclusion incomplete scientific knowledge aspects nonfinancial reporting used determine emissions factors values roche planned performed procedures needed combine emissions different gases accordance international standard assurance report therefore read assurance engagements isae revised connection roches guidelines definitions assurance engagements audits procedures well thirdparty reviews historical financial information guidelines used present selected non respect greenhouse gas emissions financial reporting performance international standard assurance engagements isae assurance engagements roches responsibility greenhouse gas statements issued roche corporate governance international auditing assurance standards sustainability committee responsible board standards require plan subject matter criteria including perform procedures obtain limited assurance selection preparation presentation whether specified nonfinancial information selected information accordance prepared material aspects accordance criteria responsibility includes design roches policies procedures well implementation maintenance related internal management reporting processes together control relevant reporting process free related control environment relation material misstatement whether due fraud data aggregation work designed form error appropriate basis reporting follow gri standards nonfinancial performance independence quality controls roche focus independent roche holding ag accordance international code limited assurance engagement substantially ethics professional accountants including less scope reasonable assurance international independence standards issued engagement relation risk assessment international ethics standards board procedures including understanding internal accountants iesba code fulfilled control procedures performed response ethical responsibilities accordance assessed risks consequently nature iesba code timing extent procedures gathering sufficient appropriate evidence deliberately pricewaterhousecoopers ag applies international limited relative reasonable assurance standard quality control accordingly engagement therefore less assurance maintains comprehensive system quality obtained limited assurance engagement control including documented policies reasonable assurance engagement procedures regarding compliance ethical procedures selected depend assurance requirements addressing soundness practitioners judgement identification process determination impacted stakeholders peer competition review summary work performed integration relevant regulatory requirements assurance procedures included amongst integration key organisational values others following work objectives report prioritisation material review application roche group aspects guidelines inspecting integration sustainability risks reviewing application roche group opportunities group risk management nonfinancial reporting contributions process adherence internal guidelines guidelines site visits management inquiry assessment processes data remotely visiting selected sites roches consolidation pharmaceuticals diagnostics divisions reviewing management nonfinancial usa switzerland china indonesia reporting processes payments selection based quantitative donations contributions key figures qualitative criteria assessing aggregation process data interviewing personnel responsible internal roche group level nonfinancial reporting data collection sites visited roche group level conducted work data determine understanding application outlined subject matter defined roches nonfinancial contributions believe evidence guidelines obtained sufficient appropriate provide assessment key figures basis assurance conclusion performing tests sample basis evidence supporting selected payments limited assurance conclusion donations contributions eg roche accident based work performed nothing come rate energy consumption coequivalent attention causing us believe emissions water usage discharge donations material aspects political parties switzerland concerning roche materiality determination process completeness accuracy adequacy group level disclosed adhere consistency principles guiding factors eg soundness review documentation analysis relevant stakeholder determination peer review relevance policies principles regulatory environment integration key reviewing relevant documentation sample organisational values objectives defined basis including roche group nonfinancial within gri standards reporting policies management reporting design sustainability risks structures documentation opportunities determination process group reviewing principles roche level disclosed function designed materiality process providing definition selected key figures mentioned scope development adherence gris disclosed within nonfinancial reporting environmental social economic reporting pricewaterhousecoopers ag birchstrasse postfach ch zurich telephone telefax wwwpwcch pricewaterhousecoopers ag member global pricewaterhousecoopers network firms separate independent legal entityindependent limited assurance report roche roche annual report stated accordance reporting criteria management reporting processes collect aggregate payments donations contributions key figures well control environment relation data aggregation working designed pricewaterhousecoopers ag christophe bourgoin helene baron zurich february published f hoffmannla roche ltd group communications basel switzerland tel wwwrochecom key dates orderdownload publications internet rochecompublications annual general meeting email baselwarehouseservicesrochecom march fax firstquarter sales media relations april tel email mediarelationsrochecom halfyear results july investor relations tel ninemonth sales email investorrelationsrochecom october corporate sustainability committee tel email corporatesustainabilityrochecomimprint roche cautionary statement regarding forward trademarks legally protected looking statements annual report contains certain forwardlooking links thirdparty pages provided statements forwardlooking statements may convenience express opinion identified words believes expects content thirdparty pages expressly anticipates projects intends seeks disclaim liability thirdparty information estimates future similar expressions use thereof discussion among things strategy goals plans intentions various factors may cause roche annual report published german actual results differ materially future english reflected forwardlooking statements contained annual report pricing reporting consists actual annual report product initiatives competitors legislative finance report contains regulatory developments economic annual financial statements consolidated conditions delay inability obtaining financial statements regards content regulatory approvals bringing products market management report per articles fluctuations currency exchange rates incorporation consists aforementioned general financial market conditions uncertainties reports exception remuneration discovery development marketing new report products new uses existing products including without limitation negative results clinical trials printed nonchlorine bleached fsccertified research projects unexpected side effects paper pipeline marketed products increased government pricing pressures interruptions production loss inability obtain adequate protection intellectual property rights litigation loss key executives employees adverse publicity news coverage statement regarding earnings per share growth profit forecast interpreted mean roches earnings earnings per share subsequent period necessarily match exceed historical published earnings earnings per share rocherehtegotregnorts f hoffmannla roche ltd basel switzerland trademarks legally protected wwwrochecom